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Abstract 
Regulation of matrix metalloproteinase (MMP) activity occurs at the levels of 
gene expression, secretion, compartmentalization, zymogen activation, and 
inhibition by tissue inhibitors of metalloproteinases (TIMPs). Membrane-type 
(MT)-MMPs are a membrane-anchored subset of MMPs. They are powerful 
ECM-degrading proteases, which may also cleave cell surface proteins and serve 
as receptors and activators for secreted proteinases. The severe connective tissue 
disorders of MT1-MMP knockout mice, and the efficacy of MT-MMPs to 
promote migratory and invasive phenotype of normal and neoplastic cells, 
emphasize the importance of these pericellular proteolytic pathways.  
We found that proteolytic processing and oligomerization are essential 
mechanisms to control MT1-MMP activity. Fibroblastic cells constitutively 
expressed MT1-MMP mRNA. MT1-MMP was synthesized as a 63-kDa 
zymogen, which was rapidly processed to the 60-kDa activated enzyme with N-
terminal Tyr
112. The MT1-MMP mRNA expression was increased two to four-
fold by phorbol myristyl acetate or concanavalin A. However, neither the relative 
levels of mRNAs for MT1-MMP or TIMP-2, nor the levels of activated enzyme 
correlated with MT1-MMP-mediated proMMP-2 activation. In human HT-1080 
fibrosarcoma cells, proMMP-2 activation correlated with the accelerated turnover 
of mature MT1-MMP through an autocatalytic inactivating cleavage to 
membrane-bound 43-kDa and soluble ~20-kDa forms. When crosslinked, MT1-
MMP was detected as homo-oligomeric cell-surface complexes composed of 
mature 60-kDa and inactivated 43-kDa species. Competitive inhibition of MT1-
MMP oligomerization through the cytoplasmic and hemopexin domains interfered 
with both proMMP-2 activation and autocatalytic MT1-MMP inactivation.  
We characterized cytoplasmic domain as a critical element to regulate the 
cellular distribution of MT1-MMP. The enzyme was clustered at the leading edge 
of migrating human Bowes melanoma cells. Cytoplasmic truncations abolished 
clustering and MT1-MMP-induced cell invasion through reconstituted basement 
membrane matrixes. On the other hand, in various cell types MT1-MMP was 
mainly localized to intracellular compartments due to endocytosis in clathrin-
coated pits. Inhibition of internalization by cytoplasmic deletion or by co-
transfection with dominant negative mutant of dynamin enhanced both the cell 
surface localization of MT1-MMP and proMMP-2 activation. 
In conclusion, MT1-MMP can be uniquely regulated at the levels of 
membrane localization and traffic, oligomerization, and autoproteolytic 
inactivation. Such cellular regulation of MT1-MMP in cooperation with adhesion, 
cytoskeletal rearrangement, and signaling pathways provides cells with 
mechanisms for precisely targeted pericellular proteolysis during cell migration 
and invasion.   
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Introduction 
Cell migration is a recurring phenomenon in development, vascular remodeling, 
wound healing, inflammatory responses, and cancer. During these processes many 
types of cells traverse basement membrane barriers and move across interstitial, 
basement membrane, or temporary matrixes. Invasive cell phenotype can be 
activated by altered interactions of cellular receptors with extracellular matrix 
(ECM) components and soluble factors. Limited proteolysis by cell surface 
proteinases such as membrane-type matrix metalloproteinases (MT-MMPs) 
allows cells to move through modified matrix. This movement involves 
continuous ECM attachments and detachments by adhesion receptors. At the cell 
surface proteinases may remodel not only ECM components, but also pericellular 
growth factors or their binding proteins and cell surface proteins including 
receptors and other proteolytic enzymes. Therefore, when targeted to the leading 
edge of migrating cells, proteolysis may not only clear the way for movement, but 
it also provides cells with directional information by modifying the environment 
in front of the cell. 
Extracellular matrix  
ECM consists of collagens, glycoproteins, proteoglycans, and 
glycosaminoglycans (Aumailley and Gayraud, 1998; Zagris, 2001). It is a highly 
organized fibrillar meshwork, which serves as substratum for cell adhesion and 
migration. ECM also constitutes barriers that maintain tissue integrity, impede cell 
migration, and regulate molecular diffusion and transfer of stimuli. In addition, 
ECM forms a dynamic cellular microenvironment, which plays an important role 
in the determination of cell phenotype (Boudreau and Bissell, 1998; Streuli, 
1999). It mediates information to and from cells directly through its components 
and by storing and modulating the function of growth factors/cytokines and other 
regulatory factors including processing enzymes and their inhibitors.  
Two structurally and functionally distinct ECM categories are the specialized 
ECMs of interstitial connective tissues and basement membranes. Blood fibrin 
clot is a temporary form of connective tissue during tissue repair, the formation of 
which is initiated by thrombin-induced cleavage of fibrinogen to fibrin.  
Interstitial matrix 
Interstitial matrix surrounds and is formed by connective tissue cells such as 
fibroblasts, osteoblasts, chondrocytes, and macrophages. It consists of a 
meshwork of protein fibers embedded in amorphous glycosaminoglycan/ 
proteoclycan substance (Aumailley and Gayraud, 1998). The composition and  
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molecular architecture of matrices differs substantially in tissues like bone, 
cartilage, tendons, ligaments, dermis, vessel walls, and the stroma of parenchymal 
organs.  
Collagens are the most abundant structural components of interstitial ECM in 
all tissues (Prockop and Kivirikko, 1995; Aumailley and Gayraud, 1998). 
Fibrillar collagens (types I, II, III, V, and XI) are the most important molecules 
in conferring mechanical strength. They are synthesized and secreted as 
procollagens with large globular N- and C-terminal propeptides, which are 
proteolytically processed to mature collagen. These triple-helical molecules, 
composed of three α-chains with series of Gly-X-Y triplet sequences, are highly 
resistant to proteolysis. In tissues, individual 2 nm thick collagen molecules 
assemble into 20-200 nM diameter fibrils. Covalent crosslinking stabilizes these 
fibrils and they can associate laterally to form fibers. Type I collagen is the major 
component of collagen fibrils in a variety of tissues including bone, skin, tendon, 
and other fibrous tissues. It is a heterotrimer of two α1(I) and one α2(I) chains. 
Type II collagen, the main component of cartilage, is a homotrimer α1(II)3. Type 
III [α1(III)3] and V [α1(V), α2(V), α3(V)] collagens form heterotypic fibrils with 
type I collagen in soft connective tissues. In bone, type I collagen is accompanied 
by type V and XI [α1(XI), α2(XI), α3(XI)] collagens. Type XI collagen also forms 
heterotypic fibrils with type II collagen.  
Non-fibrillar collagens form a rather heterogeneous group (Prockop and 
Kivirikko, 1995; Aumailley and Gayraud, 1998). Fibril-associated collagens with 
interrupted triple-helices (FACIT-collagens, type IX, XII, XIV, XVI, and XIX) 
are found in association with collagen fibrils. Type VI collagen forms microfibrils 
in most stromal connective tissues. The network-forming collagens are found in 
hypertrophic cartilage (type X), subendothelial matrices (VIII), and basement 
membranes (type IV). Long-chain collagen (type VII) is a component of 
anchoring fibrils, which stabilize the attachment of basement membranes and 
epithelia to underlying stroma. In addition, collagens with a transmembrane 
domain (type XIII and XVII), multiplexin (multiple triple-helix domain and 
interruptions) collagens (type XV and XVIII), and other proteins containing triple-
helical domains have been characterized (Prockop and Kivirikko, 1995).  
Elastic fibers are responsible for the elastic properties of tissues like lung, 
dermis, and large blood vessels (Rosenbloom et al., 1993). Elastin, the main 
component of elastic fibers, is a hydrophobic and extensively crosslinked protein, 
which is resistant to harsh physical treatments and to most proteinases. The elastic 
fibers interact with microfibrils consisting of fibrillins, other glycoproteins, and 
proteoglycans (Debelle and Tamburro, 1999; Saharinen et al. 1999).  
Various glycoproteins are present in the interstitial ECMs. Fibronectin and 
vitronectin are structural ECM glycoproteins also present in plasma, which 
mediate cell attachment to the ECM (Tryggvason et al., 1987). Fibronectins are 
high-molecular weight (235-270 kDa) glycoproteins that form disulfide-linked 
dimers and fibrillar structures. Extensive alternative splicing of a single gene 
generates different forms of fibronectins. They are composed of three types of  
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repeats, and other functional domains. Fibronectins interact with cell surface 
integrin receptors principally through RGD-sequence. They also bind to different 
matrix components including collagens, fibrin, and proteoglycans. During 
development, adhesion of embryonic cells to fibronectin is essential for their 
migration through fibronectin rich matrixes (George et al., 1993).  Upon cell 
transformation, decreased synthesis and enhanced proteolytic degradation down 
regulates fibronectins at the cell surface and ECM (Tryggvason et al., 1987; 
Vartio et al., 1983). Many other glycoproteins associate with various structural 
ECM elements. Chondronectin, for example, is a cell-associated glycoprotein in 
cartilages, which promotes the attachment of chondrocytes to type II collagen. 
Thrombospondins, tenascins, and SPARC are capable of mediating both adhesive 
and anti-adhesive interactions and can induce disassembly of focal contact 
structures (Murphy-Ullrich, 2001). 
Proteoglycans (PGs) and glycosaminoglycans (GAGs) constitute the 
amorphous substance of interstitial ECM. PGs consist of a core polypeptide chain, 
which serine and threonine residues have O-linked GAG chains of heparan, 
keratan, dermatan, or chondroitin sulfate (Iozzo, 1998). The metabolism of PGs is 
faster than that of collagens, with half-lives in tissues of a few days to several 
weeks. PGs form structural frameworks and act on matrix organization. As 
hydrophilic molecules they are important for retaining water and maintaining 
tissue volume. In addition, PGs play a role in the modulation of variety of 
biological processes including cell growth, adhesion, and invasion (Schwartz, 
2000). Many ECM associated growth factors, such as FGF and VEGF family 
members bind to heparan sulphate PGs (Taipale and Keski-Oja, 1997). Small 
leucine-rich PGs, such as decorin and fibromodulin bind to ECM components and 
participate in the regulation of collagen fibrillogenesis and organization of the 
matrix (Iozzo, 1999). They also bind TGF-β and may thus modulate the biological 
effects of this growth factor (Yamaguchi et al., 1990). Aggregan and versican, the 
main chondroitin sulphate PGs of cartilage and noncartilagenous tissues, 
respectively, interact with glycoproteins and hyaluronic acid to create extensive 
networks (Wight et al., 1992). Cell surface associated PGs such as glypicans, 
syndecans, and CD44 modulate cell adhesion.  
Basement membrane 
Basement membranes (BM) are specialized extracellular matrix sheets that 
separate epithelial and endothelial cell layers from underlying cells of collagenous 
stroma (Tryggvason et al., 1987; Yurchenco and O'Rear, 1994; Timpl, 1996). 
They are produced and assembled in co-operation by cells situated on both sides 
of the BM. The main BM components include type IV collagen, laminin, 
entactin/nidogen, and heparan and chondroitin sulfate proteoglycans (PGs). PGs 
are present in all BM structures where they may function in charge-dependent 
molecular sieving and immobilizing growth factors like FGF-2 and VEGF, which 
can bind to perlecan, the main BM heparan sulfate PG (Handler et al., 1997; Iozzo  
 11
and San Antonio, 2001). Some other components, such as SPARC (secreted 
protein, acidic and rich in cysteine), fibulin, and multiplexin collagen types XV 
and XVIII have also been found in association with basement membranes. 
Fibronectin is abundant in fetal BMs.   
Type IV collagens are trimeric proteins (~540 kDa) composed of three 
parallel α(IV) chains, which form a partially triple helical structure with numerous 
interruptions (Timpl, 1996). Six different chains have been cloned (α1(IV) to 
α6(IV)). The α1(IV) and α2(IV) chains are found in most  basement membranes, 
whereas the expression of α3-6(IV) chains is more restricted (Hudson et al., 1993; 
Yurchenco and O'Rear, 1994). The most common trimer is α1(IV)2α2(IV). Type 
IV collagen trimers can assemble into a three-dimensional network through three 
types of interactions (Yurchenco, 1994; Timpl, 1996). Four molecules can bind to 
each other at the N-terminal cysteine-rich domain (7S) to form tetramers, which 
are joined to a network structure by a dimeric interaction between C-terminal 
noncollagenous (NC1) domains. Additional lateral associations of collagen 
molecules lead to the formation of irregular three-dimensional networks, which 
are stabilized by disulfide bonds and covalent cross-links.  
Laminins are a group of large heterotrimeric glycoproteins (~400-900 kDa) 
consisting of three distinct polypeptide chains: α, β, and γ chains (Tryggvason, 
1993). At least twelve different heterotrimeric laminin isoforms assembled from 
five α, three β, and three γ chains have been characterized with different tissue 
distributions and functions (Tryggvason, 1993; Colognato and Yurchenco, 2000). 
Like type IV collagen, laminins also self-assemble through calcium dependent 
interactions involving the terminal domain of three chains to form a polymer 
network in vitro (Yurchenco and O'Rear, 1994; Timpl, 1996).  
The networks of type IV collagen and laminin are connected through various 
interactions. For example, nidogen is a sulfated glycoprotein (150 kDa), which 
bridges these molecules together (Colognato and Yurchenco, 2000). It has a C-
terminal binding site to EGF repeat of laminin γ chains that is located near the 
center of laminin trimer, and N-terminal binding site to type IV collagen. In 
addition, perlecan contains binding sites for both type IV collagen and laminin 
(Kallunki and Tryggvason, 1992). The NC1 domains of type XV and XVIII 
collagens bind to perlecan and laminin/nidogen complexes (Sasaki et al. 1998; 
2000)   
Much of the information required for the assembly of complicated ECM 
structures including collagen fibrils and type IV collagen and laminin networks 
appear to be intrinsic to the molecules. Indeed, these components can be induced 
to self-assemble in vitro in cell-free systems to structures resembling those found 
in vivo (Yurchenco, 1994).  In contrast, cell surface integrins and cytoskeletal 
components can control fibronectin fibrillogenesis (Magnusson and Mosher, 
1998), and in tissues also basement membrane assembly may be regulated through 
cellular interactions.   
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Role of extracellular matrix on cellular communication  
During embryonic development cells actively synthesize, degrade, and remodel 
ECM. A dynamic reciprocal interplay of the cells and the ECM environment 
corresponds to the flow of information that regulates cell survival, proliferation, 
differentiation, and migration during developmental processes (Zagris, 2001). The 
major players mediating and modulating this information include growth factors, 
ECM components, growth factor and adhesion receptors, intracellular signal 
transduction cascades, and extracellular modifying enzymes. In most adult tissues, 
ECM remodeling and cell proliferation are slow, the capacity for cell motility is 
repressed, and stable cell adhesion is essential for the maintenance and function of 
the tissues. For example, epithelial cells receive signals for quiescence through 
interactions with intact basement membrane and neighboring cells (Radisky et al., 
2001). In the absence of specific ECM interactions cells fail
 to correctly respond 
to growth factors and maintain or achieve an appropriate phenotype (Streuli, 
1999). Consequently, they function inappropriately or die. Indeed, changes in the 
ECM, adhesive interactions, and remodeling machinery take place early in 
malignant transformation and metastasis (Yap, 1998; Bissell and Radisky, 2001).  
Cells attach and respond to the surrounding ECM through large diversity of 
adhesion receptors including integrins, which are heterodimeric transmembrane 
glycoproteins, composed of noncovalently associated α- and β-chains. The 
combination of α- and β-chain provides each integrin with a unique range of 
specificities for a variety of ECM components and cell surface counter receptors 
(Ruoslahti, 1996). Clustering of integrins by ligand specific interactions induces 
cytoskeletal accumulation of multiprotein complexes composed of interacting 
adaptor proteins and signaling molecules. Intracellular events can then feed back 
on the expression and activity of the integrins and other gene products of the cell. 
The cellular responses depend on the composition and architecture of the ECM 
network as well as on the repertoire of cell receptors.  
Another way how ECM can affect cell behavior is by storing and mobilizing 
growth factors and cytokines. These signal to cells through receptor tyrosine (or 
serine/threonine) kinases and receptors coupled with G-proteins or signaling 
complexes with tyrosine or serine/threonine kinases and phosphatases. Both the 
remodeling of ECM components and the release or activation of ECM bound 
growth factors by proteolysis modulate transduced signals, which control cell 
phenotype. Some of these changes participate in the modulation of proteolysis by 
feedback signaling (Taipale and Keski-Oja, 1997). Interestingly, a distinct 
subfamily of discoidin domain tyrosine kinase receptors (DDR1 and DDR2), 
which signal in response to collagens rather than growth factors, have also been 
identified (Alves et al., 1995; Vogel et al., 1997). These receptors can also 
establish a feedback loop for cell phenotype through induced proteolysis (Olaso et 
al., 2001).     
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Extracellular matrix remodeling 
Coordinated degradation of ECM is involved in various physiological tissue 
remodeling processes such as tissue morphogenesis and growth, angiogenesis, 
trophoblast implantation, bone remodeling, wound healing, and involution of 
postpartum uterus or postlactation mammary gland (Vu et al., 2000; Sternlicht and 
Werb, 2001; Zagris, 2001). Both excessive and deficient proteolysis are associated 
with a number of pathological conditions like arthritis, periodontitis, chronic 
wounds, and scleroderma (Birkedal-Hansen, 1995; Sternlicht and Werb, 2001). 
During tumor invasion, neoplastic cells utilize proteolytic and invasive 
mechanisms in a controlled but abnormally regulated fashion to allow cell 
attachment, localized degradation of the ECM, and cell migration through the 
digested barrier (Stetler-Stevenson and Yu, 2001).  
The remodeling of the differentiated ECMs of various organs and the 
subepithelial or subendothelial basement membranes is dependent on the 
concerted action of several proteinases from different proteinase families. 
Proteases are classified into exo- or endopeptidases according to the terminal or 
internal cleavage site on the target proteins (Woessner, 1998). Endopeptidases are 
divided into the major classes of serine, cysteine, aspartic, and metalloproteinases 
based on amino acid sequences and cofactors determining their catalytic activity 
and mechanism. Matrix metalloproteinases (MMPs) form one of the four 
subfamilies that belong to metzincins, which in turn is one of numerous 
metalloproteinase superfamilies (Woessner, 1998). 
Matrix metalloproteinases 
The MMP family consists currently of 26 distinct but structurally related 
vertebrate enzymes, and 21 characterized human homologues with partially 
overlapping substrate specificities (Nagase and Woessner, 1999; Pei, 1999b,c; 
Velasco et al., 1999; Park et al. 2000; Lohi et al. 2001). They are zinc-dependent 
neutral endopeptidases, whose activation requires the removal of the N-terminal 
prodomain (Fig.1). MMPs function in the degradation and remodeling of different 
ECM proteins and proteoglycans, but recent studies also suggest various other 
roles for these enzymes (Tables 1 and 2). For example, MMPs can cleave and thus 
modulate the assembly and activity of membrane or ECM-bound cytokine 
precursors, chemokines, growth factors, hormone receptors, growth factor binding 
proteins, and proteinase inhibitors (McCawley and Matrisian, 2001; Sternlicht and 
Werb, 2001). MMP activity is regulated by diverse mechanisms at the levels of 
gene transcription, mRNA stability, enzyme secretion and binding, zymogen 
activation, and inhibition by endogenous inhibitors to achieve precise proteolysis 
during normal tissue remodeling (Nagase and Woessner, 1999). Dysregulated 
MMP activity is characteristic to a number of pathological conditions such as 
chronic wounds, arthritis, periodontitis, cardiovascular disease, and cancer.   
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Collagenases:
MMP-1, -8,and -13
Stromelysins and others: 
20,  MMP-3, -10, -12, -19, and -
Gelatinases:
MMP-2 and -9
Prodomain
Catalytic
Hinge
Pexin-like
MMP-11 and -28
MMP-7 and -26
Signal peptide
Prototype
Cys Zn
++
Cys Zn
++
Cys Zn
++
Cys Zn
++
Cys Zn
++
Zn
++ Cys
Fibronectin type II
 repeats
Membrane-bound MMPs:
MMP-14, -15, -16, and -24
Cys Zn
++
Cys Zn
++ TM
MMP-23
MMP-17 and -25
Zn
++ C.A. Ig-like GPI
 
Figure 1. Domain structure of MMPs. TM, transmembrane domain; GPI, glycosyl 
phospatidyl inositol-anchor; C.A., Cysteine array 
MMPs can be divided into subgroups based on structural and functional 
criteria (Fig. 1). They are either soluble proteins or membrane proteins anchored 
to cellular membranes by type I or type II transmembrane domains or by a 
glycosyl-phosphatidyl inositol (GPI)-anchor. The soluble secreted MMPs have 
been further classified to subgroups of collagenases, which can degrade fibrillar 
collagens, gelatinases, having high activity against gelatin and type IV collagen, 
and stromelysins, matrilysins and other MMPs, which degrade variety of ECM 
components. The membrane-anchored MMPs form the group of membrane-type 
matrix metalloproteinases. 
Collagenases 
Collagenases-1, -2, and -3 (MMP-1, MMP-8, and MMP-13, respectively) are the 
main secreted neutral proteinases, which can initiate the degradation of native 
helix of fibrillar collagens (Jeffrey, 1998). The hemopexin domains of these 
MMPs are essential for specific binding and cleavage of this substrate (Allan et 
al., 1991; Clark and Cawston, 1989; Knäuper et al., 1996a, 1997) All three 
collagenases can cleave a specific site (Gly
775-Ile/Leu
776) at each α-chain of the 
trimeric collagen molecule. The resulting N-terminal ¾ and C-terminal ¼ 
fragments are spontaneously denatured at 37°C to gelatin, which can be further  
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degraded by other proteinases. Three collagenases have overlapping activities on 
the fibrillar collagen types I, II, and III, but their substrate preferences are 
different. MMP-1 displays highest catalytic efficiency against type III relative to 
type I collagen, whereas MMP-8 has reversed preference, and MMP-13 
preferentially cleaves collagen type II. MMP-13 also displays higher gelatinase 
activity and has broader substrate specificity than MMP-1 and –8. MT-MMPs  
(Ohuchi et al., 1997) and MMP-2 (Aimes and Quigley, 1995; Patterson et al., 
2001) are also able to degrade fibrillar collagens to the ¾ and ¼ fragments. 
MMP-1 was the first MMP discovered based on its activity in 
metamorphosing tadpole tail (Gross and Lapiere 1962). It was also the first MMP 
purified to homogeneity (Stricklin et al., 1977) and cloned as a cDNA (Goldberg 
et al., 1986). Fibroblasts of various origins, chondrocytes, osteoblasts, endothelial 
cells, keratinocytes, hepatocytes, macrophages and monocytes, eosinophils, and 
tumor cells secrete MMP-1 in vitro (Jeffrey, 1998). MMP-8 is synthesized by 
polymorphonuclear leukocytes during their maturation in bone marrow, stored in 
intracellular granules, and released in response to external stimuli (Hasty et al., 
1990). In addition, chondrocytes, rheumatoid synovial fibroblasts, gingival 
fibroblasts, bronchial epithelial cells, and melanoma cells express MMP-8 (Cole 
et al., 1996; Hanemaaijer et al., 1997; Abe et al., 2001; Prikk et al., 2001). MMP-
13 is expressed during fetal bone development, postnatal bone remodeling, and 
gingival wound repair (Johansson et al., 1997b; Ravanti et al., 1999). In addition, 
MMP-13 expression has been associated with pathological conditions such as 
severe chronic inflammation in osteoarthritic cartilage, rheumatoid synovium, and 
chronic wounds, as well as malignant tumor invasion (Airola et al., 1997; 
Johansson et al., 1997a; Vaalamo et al., 1997; Balbin et al., 1999) 
Gelatinases 
MMP-2 (gelatinase A, 72-kDa gelatinase) and MMP-9 (gelatinase B, 92-kDa 
gelatinase) differ from the other MMPs by containing three head-to-tail repeats 
homologous to the type II repeat of the collagen-binding domain of fibronectin 
(Collier et al., 1988). These domains are required for gelatinases to bind and 
cleave collagen (Keski-Oja and Todaro, 1980; Vartio et al., 1981; Vartio et al., 
1982b; Keski-Oja and Vaheri, 1982; Murphy et al., 1994; Steffensen et al., 1995) 
and elastin (Shipley et al. 1996). The hemopexin domain does not affect MMP-2 
binding to collagen (Allan et al., 1995), but similarly to collagenases it is critical 
for the initial cleavage of the triple helical type I collagen (Patterson et al., 2001). 
The hinge domain of MMP-9 contains an additional type V collagen-like insert 
(Wilhelm et al., 1989). Unlike other MMPs, the MMP-2 and -9 proenzymes can 
bind TIMP-2 and -1, respectively (Olson et al., 1997; O'Connell et al., 1994) 
A wide range of normal and transformed cells of fibroblastic, endothelial, and 
epithelial origin constitutively express MMP-2 (Vartio and Vaheri, 1981; Collier 
et al., 1988; Huhtala et al., 1991; Salo et al., 1983; Salo et al., 1991; Tryggvason 
et al., 1990). During development it is widely expressed by stromal cells 
(Reponen et al.,  1992).  Expression  of  MMP-9  is more  restricted  and  is often   
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Table 1.   Secretory matrix metalloproteinases 
 Potential  substrates 
Enzyme name(s)  Matrix components  Others 
Collagenases 
MMP-1/collagenase-1  
(fibroblast collagenase, 
interstitial collagenase) 
Col I, II, III, VII, VIII, X, XI; gelatin; 
entactin; aggrecan; tenascin; MBP; 
perlecan; IGFBP-2, 3; 
ProMMP-1, 2; casein, α2M; 
α1PI; α2AC; proTNFα 
MMP-8/ collagenase-2 
(neutrophil collagenase) 
Col I, II, III, gelatin; entactin; 
aggrecan; tenascin 
ProMMP-8; α2M; α1PI  
MMP-13/ collagenase-3  Col I, II, III, IV, IX, X, XIV; gelatin; 
entactin; aggrecan; tenascin; 
osteonectin; fibrinogen/fibrin 
ProMMP-9; 13; α2M; α2AC; 
PAI;  
Gelatinases (type IV collagenases) 
MMP-2/ gelatinase A  
(72-kDa gelatinase) 
Gelatin; elastin; fibronectin; Col I, IV, 
V, VII, X, XI; laminin; aggrecan; 
vitronectin; decorin; MBP; IGFBP-3/5 
ProMMP-1, 2,13; 
plasminogen; casein; α2M; 
α1PI; α2AC; proTNFα; 
proTGFβ2; proIL1β; MCP3; 
FGFr1 
MMP-9/ gelatinase B 
(92-kDa gelatinase) 
Gelatins; Col IV, V, VII, XI, XIV, 
XVII; elastin; fibrillin; fibronectin; 
aggrecan; fibrinogen/fibrin; MBP 
Plasminogen; casein; α2M; 
α1PI; proTNFα; proTGFβ2; 
proIL1β 
Stromelysins, matrilysins and others 
MMP-3/ stromelysin-1  
 
Fibronectin; laminin; gelatin; Col III, 
IV, V, VII, IX, X, XI; elastin; decorin; 
nidogen; perlecan; aggrecan; tenascin; 
fibrin/fibrinogen; fibrillin; entactin; 
vitronectin; IGFBP-3 
ProMMP-1, 3,7,8,9,13; 
plasminogen; casein; α2M; 
α1PI; α2AC; proTNFα; E-
cadherin; proIL-1β; proHB-
EGF 
MMP-10/ stromelysin-2  Fibronectin; laminin; gelatin; Col III, 
IV, V, II, IX, X, XI; decorin; elastin; 
nidogen; fibrin/fibrinogen; fibrillin; 
entactin; tenascin; vitronectin; 
aggrecan;  
ProMMP-1, 8, 10 
MMP-11/ stromelysin-3  Laminin; fibronectin; aggrecan; 
IGFBP-1 
Α2M; α1PI 
MMP-7/ matrilysin-1  
(PUMP-1) 
Fibronectin; laminin; Col IV; gelatin; 
aggrecan; decorin; nidogen; elastin; 
fibrillin; laminin; MBP: osteonectin; 
tenascin; vitronectin  
ProMMP-2, 7; casein; α1PI; 
pro α-defensin; FasL; β4 
integrin; E-cadherin; 
plasminogen; proTNFα 
MMP-26/ matrilysin-2  
(endometase) 
Col IV; gelatin; fibronectin; 
fibrin/fibrinogen 
ProMMP-9; casein; α1PI 
MMP-12/  
macrophage 
metalloelastase 
Elastin; fibronectin; fibrinogen/fibrin; 
laminin 
Plasminogen; casein 
MMP-19/ (RASI)  Col IV; gelatin; fibronectin; tenascin; 
aggrecan; COMP 
 
MMP-20/ enamelysin  Amelogenin; aggrecan; COMP   
MMP-23/ CA-MMP  Gelatin    
MMP-28/ epilysin  ND Casein 
Modified from (McCawley and Matrisian, 2001; Sternlicht and Werb, 2001). Abbreviations: Col, 
collagen; COMP, cartilage oligomeric matrix protein; IGFBP, insulin-like growth factor binding 
protein; Ln, laminin; MBP, myelin basic protein; PAI, plasminogen activator inhibitor; α2M, α2 
macroglobulin; α1PI, α1 proteinase inhibitor; α2AC, α2 antichymotrypsin; ND, not determined  
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low in normal tissues, but it can be induced when tissue remodeling occurs during 
development, wound healing and cancer invasion. MMP-9 is secreted by alveolar 
macrophages, polymorphonuclear leukocytes, osteoclasts, keratinocytes, and 
invading trophoblasts, and by several transformed cell lines, but not by 
fibroblastic cells (Hibbs et al., 1985; Saarialho-Kere et al., 1993; Vartio et al., 
1982a; Reponen et al., 1995; Reponen et al., 1994; Salo et al., 1991). In vitro both 
gelatinases can degrade a variety of proteins, but the in vivo substrates are largely 
unknown (Sternlicht and Werb, 2001). Based on their ability to degrade type IV 
collagen and laminin, the main components of BMs and the correlation between 
the levels of MMP-2 expression and activity, and invasive potential of certain 
cancer cells, gelatinases, especially MMP-2 have been suggested to degrade BM 
components  in vivo (Tryggvason et al., 1987). Both gelatinases can also 
efficiently degrade partially denatured collagens of all genetic types following the 
initial cleavage by collagenases (Overall et al., 1989). MMP-2 but not MMP-9 
selectively cleaves γ2-chain of laminin 5 and promotes cell migration in a 
mammary epithelial cell model (Giannelli et al., 1997). MMP-9 has been 
suggested to affect angiogenesis by releasing ECM bound VEGF (Vu et al., 
1998). The α1-proteinase inhibitor (α1-PI) is an in vivo substrate for MMP-9 in 
skin blisters (Liu et al., 2000) 
Stromelysins, matrilysins, and other MMPs 
Stromelysins include stromelysin-1, -2 and -3 (MMP-3, MMP-10, and MMP-11, 
respectively). Matrilysins-1 and -2 (MMP-7 and MMP-26, respectively) and 
metalloelastase (MMP-12) are other MMPs with broad substrate specificities. 
Matrilysins are the smallest MMPs (~28-kDa) that lack the C-terminal 
hemopexin-like domains present in other MMPs. The domain structures of 
stromelysins resemble those of collagenases. However, they are unable to cleave 
native fibrillar collagens. Stromelysin-3 is inactive against many ECM 
components; instead it can cleave proteinase inhibitors, α2-magroglobulin (α2M) 
and α1-PI (Pei et al., 1994), and insulin-like growth factor binding protein  (IGF-
BPs; Manes et al., 1997). It also differs from most secreted MMPs by having 
recognition sequence for proprotein convertases between the pro- and catalytic 
domains. Some recently characterized MMPs including CA-MMP (MMP-23), and 
epilysin (MMP-28) also contain insertions with similar basic sequences (Pei 
1999a; Velasco et al., 1999; Lohi et al., 2000).  
Membrane-type matrix metalloproteinases  
The finding that plasma membranes from various tumor cells contained proMMP-
2 activator sensitive to MMP inhibitors first suggested the existence of 
membrane-bound MMPs (Brown et al., 1993; Strongin et al., 1993b). Sato et al. 
(Sato et al., 1994) cloned the cDNA for MT1-MMP (MMP-14), encoding a 63-
kDa type I transmembrane protein that could activate proMMP-2 and promote cell  
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invasion. To date, six additional cDNAs for membrane-bound MMPs have been 
cloned. Their protein products have been named MT-MMPs -2, -3, -4, -5, and –6, 
and CA-MMP (MMP-14, -15, -16, -17, -24, -25, and –23, respectively; Will and 
Hinzmann, 1995; Takino et al., 1995; Puente et al., 1996; Llano et al., 1999; Pei, 
1999a, b, c; Velasco et al., 1999). MT-MMPs have recently gained considerable 
attention, partly because of the marked abnormalities associated with MT1-MMP 
knockout mice in contrast to the subtle phenotypes of mice deficient of secretory 
MMPs (Holmbeck et al., 1999; Shapiro, 1998; Zhou et al., 2000). MT1-MMP is 
also more active in ECM degradation and promoting cell invasiveness in 
experimental models than its soluble form or the secretory MMPs, highlighting 
the importance of the cell surface localization and cellular regulation of these 
enzymes (Hiraoka et al., 1998; Holmbeck et al., 1999; Hotary et al., 2000).  
MMP-23 differs from all other characterized MMPs by having unique 
cysteine-rich, proline-rich, and IL-1 type II receptor-like domains instead of the 
C-terminal hemopexin-like domain (Pei, 1999a; Velasco et al., 1999). It has also 
an atypical N-terminal prodomain that lacks the conserved “cysteine switch” 
sequence, but contains a potential membrane spanning region. This binds 
proMMP-23 to the cellular membranes as a type II transmembrane protein. A 
single proteolytic cleavage between the pro- and catalytic domains by furin both 
activates the proenzyme and releases the activated soluble enzyme from the cell 
membrane (Pei et al., 2000).   
Structural features  
MT1-MMP has a similar domain structure with most MMPs (Fig. 1; Sato et al., 
1994). An N-terminal hydrophobic signal sequence is followed by the propeptide 
domain. The subsequent catalytic domain contains two zinc ion (catalytic and 
structural) and two calcium ion-binding sites (Fernandez-Catalan et al., 1998). A 
proline-rich hinge region separates the hemopexin-like domain from the catalytic 
domain. This hemopexin domain consists of four blades, which are stabilized 
around central calcium ion by an intramolecular disulfide bond between cysteine 
residues at both ends of this domain (Li et al., 1995; Libson et al., 1995; 
Morgunova et al., 1999).  
Three insertions not found in most secreted MMPs determine many distinct 
features of MT1-MMP: 1) an 11-aa insertion between the propeptide and the 
catalytic domain that contains an RRKR sequence, a recognition motif for 
cleavage by subtilisin-like Golgi associated proteinases (present also in MMP-11, 
MMP-23 and MMP-28); 2) an 8-aa insertion in the N-terminal part of the catalytic 
domain (MT-loop); and 3) a C-terminal insertion containing a stretch of 24-aa 
hydrophobic sequence (a transmembrane domain) followed by a 20-aa 
cytoplasmic domain (Sato et al., 1994; Cao et al., 1995). The crystal structure of 
MT1-MMP catalytic domain in complex with TIMP-2 has been characterized 
(Fernandez-Catalan et al., 1998). The catalytic domain consists of a five-stranded 
β sheet and three α helixes characteristic for MMP fold (Fig. 2). The structure  
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differs from classical MMP fold mostly by containing two large insertions remote 
from the active site cleft: the long flexible loop between βII and βIII strands called 
as “MT-MMP loop” and the elongated loop between βV strand and αB helix 
(Fernandez-Catalan et al., 1998). 
Based on their membrane anchoring mechanisms the six MT-MMPs can be 
divided to type I transmembrane proteins and GPI-anchored proteins. (Will and 
Hinzmann, 1995; Takino et al., 1995; Puente et al., 1996; Llano et al., 1999; Pei, 
1999b; Pei, 1999c; Velasco et al., 2000). MT2-, MT3-, and MT5-MMPs (MMP-
15, -16, and –24) are type I transmembrane proteins homologous to MT1-MMP 
and contain the three insertions found in MT1-MMP. The sequence identity of the 
catalytic domains of these MT-MMPs is over 65%. In contrast, MT4-, and MT6-
MMPs (MMP-17 and MMP–25) lack the cytoplasmic tail and the hydrophobic 
region at the C-terminus acts as a signal for GPI-anchorage (Itoh et al., 1999; 
Kojima et al., 2000). MT4-, and MT6-MMPs contain the potential furin cleavage 
sites, but lack the 8-aa insertion present in the catalytic domains of other MT-
MMPs.  
 
Figure 2. Ribbon structure of MT1-MMP catalytic domain (dark grey)/ TIMP-2 (light 
gray) complex (Fernandez-Catalan et al., 1998). The α-helixes (HA-HC) and β-sheets 
(SI-SVI) of MT1-MMP catalytic domain as well as zinc and calcium ions have been 
indicated. 
Activity and substrate specificity  
The substrate specificities of the MT-MMPs have been studied with recombinant 
catalytic domains and transmembrane deletion mutants and with wild-type 
enzymes expressed in bacterial and mammalian expression systems (Table 2).   
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Table 2.   Membrane-type matrix metalloproteinases 
 Potential  substrates 
Enzyme name(s)  Matrix components  Others 
 
MMP-14/  
MT1-MMP 
Col I, II, III; gelatin; fibronectin; Ln-1, -
5; vitronectin; aggrecan; tenascin; 
nidogen; perlecan; fibrinogen/fibrin; 
fibrillin  
ProMMP-2, -13; α1PI; α2M; 
CD44; CXCL12; proTNFα; 
tissue transglutaminase; αv-
integrin 
MMP-15/  
MT2-MMP 
Col I; gelatin; fibronectin; Ln-1; 
vitronectin; aggrecan; tenascin; nidogen; 
perlecan; fibrinogen/fibrin 
ProMMP-2; cell surface tissue 
transglutaminase; 
MMP-16/ 
MT3-MMP 
Col III; gelatin; casein; fibronectin; Ln-1; 
vitronectin; aggrecan 
ProMMP-2,  
MMP-17/ 
MT4-MMP 
Gelatin; fibrillin; fibronectin  ProTNFα 
MMP-24/  
MT5-MMP 
Heparan and chondroitin sulphate 
proteoglycans; gelatin; fibronectin 
ProMMP-2 
MMP-25/  
MT6-MMP 
Col IV; gelatin; fibrinogen/fibrin; 
fibronectin; vitronectin 
α1PI 
Modified from (McCawley and Matrisian, 2001; Sternlicht and Werb, 2001). Abbreviations: Col, 
collagen; Ln, laminin; α2M, α2 macroglobulin; α1PI, α1 proteinase inhibitor; ND, not determined 
These studies have demonstrated that MT1-, MT2-, MT3-, and MT5-MMP are all 
potent matrix-degrading proteases. The catalytic domains of MT1- and MT2-
MMP degrade gelatin, fibronectin, tenascin, nidogen, aggrecan, perlecan, and 
laminin and process a proTNF-α fusion protein to release mature TNF-α (Pei and 
Weiss 1996; d'Ortho et al., 1997). MT1-MMP retaining the hemopexin domain is 
able to specifically cleave native type I and type III collagens into the   3/4-1/4   
fragments typical of the collagenases (Ohuchi et al., 1997), whereas the catalytic 
domain alone does not have this activity. MT1-MMP is also an efficient 
fibrinolytic proteinase (Hiraoka et al., 1998). By quantitative analyses of the 
activities of soluble mutants, MT3-MMP was found to be five fold more efficient 
in cleaving type III collagen than MT1-MMP, whereas MT3-MMP was inefficient 
in cleaving fibrillar type I collagen (Shimada et al., 1999). Soluble MT3-MMP 
also digests aggrecan, gelatin, fibronectin, vitronectin, laminin-1, α1-PI, and α2M. 
Proteoglycans are the preferred substrates for mouse MT5-MMP (Wang et al., 
1999a). At the surface of cultured cells MT1-MMP can also cleave several 
receptors, such as CD44, cell surface tissue transglutaminase, and integrin αV, α3, 
and α5 subunits (Belkin et al., 2001; Deryugina et al., 2001b; Kajita et al., 2001; 
Ratnikov et al., 2001). Recently, receptor of complement component 1q (gC1qR) 
was found to be susceptible to MT1-MMP proteolysis in vitro and in cell cultures 
(Rozanov et al., 2001b). Soluble forms of MT1-, MT2-, MT3-, and MT5-MMP 
are efficient in initiating the proMMP-2 activation by cleavage of its prodomain.  
The catalytic activity of MT4- and MT6-MMPs differs from those of the 
other MT-MMPs. They are ineffective in MMP-2 activation (Itoh et al., 1999; 
Kojima et al., 2000). They are also ineffective against many ECM components, 
but can cleave gelatin, fibrinogen, and fibrin. MT4-MMP has also TNF-α- 
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converting activity (English et al., 2000; English et al., 2001b; Wang et al., 
1999b). 
As is the case for the other MMPs, the in vivo substrates of the MT-MMPs 
are largely unknown. Previously, MT1-MMP was considered mainly as proMMP-
2 activator, and it can also activate proMMP-13 (Knäuper et al., 1996b). However, 
the characterization of the severe phenotype of MT1-MMP deficient mice, in 
contrast to the subtle phenotype of MMP-2 deficient mice suggests important 
MMP-2 independent roles for MT1-MMP in connective tissue metabolism and 
angiogenesis (Holmbeck et al., 1999; Zhou et al., 2000; Itoh et al., 1997). In 
addition, overexpression of MT1-MMP in MDCK cells, which do not express 
MMP-2, renders invasion-incompetent cells able to invade fibrin gels and type I 
collagen matrix (Hiraoka et al., 1998; Hotary et al., 2000). In this experimental 
system the overexpression of soluble MMPs has no effect on cell invasion, 
highlighting the significance of the direct ECM degrading activity of MT1-MMP 
during invasive processes. On the other hand, MMP-2 activation is impaired in 
tissues of MT1-MMP and TIMP-2 deficient mice, indicating that the function of 
MT1-MMP and TIMP-2 is important also for MMP-2 activation in vivo (Caterina 
et al., 2000; Wang et al., 2000; Zhou et al., 2000). 
Regulation of MT-MMP activity 
Gene expression 
Regulatory mechanisms of MMP gene transcription exist for cell-type and 
stimulus specificity (Birkedal-Hansen et al., 1993; Westermarck and Kähäri, 
1999). The expression of many MMPs is confined to only a few cell types or 
tissues, suggesting the presence of cell or tissue-specific promoters, enhancers 
and/or silencers (Frisch and Morisaki, 1990; Harendza et al., 1995). Most MMP 
genes are not expressed in normal adult tissues or by unstimulated cells in vitro, 
but their expression is markedly induced by growth factors, pro-inflammatory 
cytokines, and phorbol esters (Birkedal-Hansen et al., 1993; Westermarck and 
Kähäri, 1999). The induction is mediated by the TPA-responsive element (TRE) 
and the polyomavirus enhancer element (PEA3) present in the promoter regions of 
these MMPs (Birkedal-Hansen et al., 1993; Westermarck and Kähäri, 1999). In 
contrast, MT1-MMP is constitutively expressed in vitro by different cell types 
including fibroblasts, endothelial cells, and smooth muscle cells, and its 
expression is only modestly enhanced by PMA, TNF-α, and the lectin 
concanavalin A (ConA), not affected by TGF-β, and decreased by dexamethasone 
(Lohi and Keski-Oja, 1995; Migita et al., 1996). In addition, the mRNAs for all 
MT-MMPs are detectable by Northern blot analysis in normal human tissues 
(Table 3). MMP-2 is also constitutively expressed in most fibroblastic cells, and  
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Table 3.   Expression of membrane-type matrix metalloproteinases in human tissues 
MT-MMP#  1 2 3 4 5 6 
Brain  - - ++  +++  +++ - 
Lung  +++ +  ++    + + 
Liver  -/+ ++ ++ -  - - 
Heart  + ++  -  -  - - 
Placenta  +++ ++  ++  -  - - 
Pancreas  + ++  -  -  + - 
Kidney  ++ ++ -  -  ++ - 
Ovary  +++ -    ++  - - 
Intestine  +++ ++      - - 
Prostate  ++ -    -  - - 
Spleen  + -    -  - + 
Testis  + ++    ++  - - 
Colon  + ++    ++  - - 
Muscle  + ++  -  -  - - 
Leukocytes  - -   ++  - +++ 
Expression levels: +++, high; ++, considerable; +, detectable by Northern blotting; -, very low or 
not detectable (Will and Hinzmann, 1995; Takino et al. 1995; Puente et al. 1996; Llano et al. 1999; 
Pei 1999; Velasco et al. 2000). The expression levels of each MT-MMP are relative only to the 
expression levels of the same MT-MMP in different tissues. 
its expression is enhanced by TGF-β but not by phorbol esters (Collier et al., 
1988). The MT1-MMP and MMP-2 genes lack a conserved TATA sequence and 
AP-1 binding sites (Huhtala et al., 1990; Lohi et al., 2000). In addition, both MT1-
MMP and MMP-2 promoters have Sp1 binding sites that are important for basal 
promoter activity. Coexpression of MT1-MMP with MMP-2 and TIMP-2 during 
mouse embryogenesis suggests similar regulation of gene transcription in vivo 
(Kinoh et al., 1996; Apte et al., 1997). The expression of both MT1-MMP and 
MMP-2 is down regulated after birth, whereas the expression of TIMP-2 remains 
high favoring tissue stability (Kinoh et al., 1996; Apte et al., 1997). 
MT1-MMP expression is regulated by cytoskeleton-ECM interactions. It is 
induced in fibroblasts and endothelial cells by culture in three dimensional 
collagen matrixes, by mechanical stretching, and by treatment of the cells with the 
cytoskeleton disrupting agent cytochalasin D (Ailenberg and Silverman, 1996; 
Gilles et al., 1997; Tomasek et al., 1997; Tyagi et al., 1998; Haas et al., 1998; 
Haas et al., 1999). Therefore, signaling pathways initiated through collagen 
binding β1 integrins may regulate MT1-MMP expression (Haas and Madri, 1999). 
Interestingly, the induction of MT1-MMP occurs when the cells are cultured on or 
within a type I collagen gel, but does not occur when cells are grown on a thin 
coating of type I collagen (Azzam and Thompson, 1992; Haas et al., 1998; 
Tomasek et al., 1997). MT1-MMP expression levels are also higher in fibroblasts 
cultured on a floating or stress-relaxed collagen lattice compared with the  
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expression levels in actin stress-fiber containing fibroblasts cultured in stabilized 
lattices (Tomasek et al., 1997). Therefore, the induction could involve, in addition 
to ligand-specific integrin interaction, alterations in mechanical force and in the 
assembly of actin cytoskeleton.  
In endothelial cells cultured in collagen matrix, increased binding of Egr-1 
transcription factor to MT1-MMP promoter correlates with enhanced MT1-MMP 
transcription (Haas et al., 1999). At the MT1-MMP promoter the consensus 
binding sites for Sp1 and Egr-1 are overlapping, whereas MMP-2 promoter does 
not contain Egr-1 binding sites, thus allowing cells to specifically upregulate 
MT1-MMP. Interestingly, the induction of Egr-1 occurs in response to potential 
angiogenesis initiators such as wound formation, mechanical stress, and fluid 
shear stress (Khachigian et al., 1996; Silverman and Collins, 1999). In murine 
melanoma B16F10 cells osteopontin, an ECM protein that interacts with αVβ3 
integrin and induces cell migration and invasion, enhances MT1-MMP expression 
via an NF-κB mediated pathway (Philip et al., 2001). Cytokines appear to regulate 
MT1-MMP expression during inflammation. Although TNF-α alone has little 
effect on MT1-MMP gene expression in cultured fibroblasts (Han et al., 2001), 
activation of NF-κB signaling synergistically by TNF-α and type I collagen 
induces MT1-MMP expression in skin fibroblasts (Han et al., 2001). TNF-α, IL-
1α, and IL-1β also up regulate MT1-MMP gene expression in vascular endothelial 
cells (Rajavashisth et al., 1999). In human monocytes MT1-MMP is induced by 
lipopolysaccharide through prostaglandin-cAMP dependent pathway 
(Shankavaram et al., 2001).  
Zymogen activation  
All MMPs are synthesized as latent zymogens containing an about 10-kDa amino 
terminal globular prodomain that protrudes into the active site of the enzyme and 
maintains its latency (Becker et al., 1995; Morgunova et al., 1999). A cysteine-
zinc bond links the unpaired cysteine residue in the prodomain to the catalytic 
zinc ion preventing the access of a water molecule that is necessary for catalysis 
(Bode et al., 1999). The sequence surrounding the cysteine in the prodomain, 
(K)PRCGV/NPD(V), and the zinc binding sequence in the catalytic domain, 
HEXGHXXGXXH, are the two best-conserved sequences in MMPs (Nagase and 
Woessner, 1999).  The activation of the soluble proMMPs can be accomplished in 
vitro by detergents, chaotropic agents, oxidants, mercurial compounds, sulfhydryl 
reagents, and acidic pH, which expose the prodomain cysteine by conformational 
change, and cause the disruption of Cys-zinc bond (“cysteine switch”; Springman 
et al., 1990; Van Wart and Birkedal-Hansen, 1990). In addition, cleavage of the 
prodomain by various serine, cysteine, and metalloproteinases leads to unfolding 
and exposure of the remaining part of propeptide and disruption of the cysteine-
zinc bond. The initial cleavages occurring usually in the flexible, exposed αI-αII 
loop is followed by a series of (autocatalytic) cleavages leading to the generation 
of the mature enzyme.    
 24
In most cases the proteolytic activation of proMMP occurs extracellularly. 
Because several soluble enzymes can activate most secreted MMPs, their 
availability may be as important as the type of the activating enzyme(s) in vivo 
(Mignatti and Rifkin, 1993, 2000). The lack of activation of many MMPs (MMP-
3, MMP-9, MMP-12, and MMP-13) in macrophages of uPA deficient mice 
suggests an important role of the cell surface plasminogen activator/plasmin 
system on the activation of some secreted MMPs in vivo (Carmeliet et al., 1997).  
Characterization of constitutive intracellular activation of prostromelysin-3 
(MMP-11) by the Golgi-associated endopeptidase furin described a novel 
mechanism for the activation of MMPs (Pei and Weiss, 1995). A basic sequence 
RXRXKR present in the prodomain was found to signal the cleavage as shown by 
site-directed mutagenesis, deletion mutants, and switching of this region to MMP-
1, where it also caused the intracellular activation of this MMP. All MT-MMPs 
contain similar basic recognition sequences (RXK/RR) at the C-terminal ends of 
the prodomains, and also these MMPs appear to be activated during transport to 
the cell surface. Indeed, co-expressed furin intracellularly activates truncated 
MT1-MMP lacking the transmembrane and cytoplasmic domains, and an 
irreversible inhibitor of furin, the Pittsburgh mutant of α1-PI prevents the 
activation (Pei and Weiss, 1996; Sato et al., 1996). The N-terminus of furin-
activated enzyme is identical to the endogenous MT1-MMP purified from HT-
1080 cells (Strongin et al., 1995). Soluble proMT1-MMP can also be activated by 
plasmin. However, the initial cleavage by plasmin occurs after RRK sequence 
leading to, after further processing, only partially the same N-terminus with wild 
type activated MT1-MMP (Okumura et al., 1997). In addition, extracellularly 
added serine proteinase inhibitors appear to have no effect on MT1-MMP activity. 
Furthermore, treatment of human fibroblastic and fibrosarcoma cells as well as 
several melanoma cells with the synthetic furin inhibitor Dec-RVKR-CH2Cl 
inhibits the processing of full-length MT1-MMP and MMP-2 activation (Kurschat 
et al., 1999; Maquoi et al., 1998; Sato et al., 1999). Yana and Weiss (Yana and 
Weiss, 2000) described furin-dependent and independent pathways for MT1-
MMP processing, which were affected by the membrane tethering of the enzyme. 
They also identified two sets of basic motifs as potential substrates for proprotein 
convertases in the MT1-MMP prodomain. MT3-MMP is also activated by furin in 
the trans-Golgi networks of MDCK cells (Kang et al., 2002). However, the 
potentially cell-type specific regulation of MT-MMP activation by different furin-
like proprotein convertases during yet uncharacterized trafficking events from 
endoplasmic reticulum to the cell surface is still incompletely understood. 
Furthermore, Cao et al. (Cao et al., 1996; Cao et al., 1998; Cao et al., 2000) have 
questioned the requirement of this proteolytic removal of the prodomain. In fact, 
they have suggested that the prodomain is required for the binding of TIMP-2 to 
the catalytic domain and for the catalytic activity of MT1-MMP (Cao et al., 1998; 
Cao et al., 2000). A possible explanation for this requirement of the prodomain 
may be its chaperone function that is essential for folding and trafficking of the 
enzyme (Cao et al., 2000). This function is dependent on the conserved Y
42GYL
45 
sequence within the propeptide domain (Pavlaki et al., 2001). The level of  
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catalytic MMP activity obtained by conformational changes without removal of 
the prodomain is currently unclear (Bannikov et al. 2002). 
Metalloproteinase inhibitors   
Endogenous inhibitors like tissue inhibitors of metalloproteinases and serum α2-
macroglobulin (α2M) can inhibit the activated MMPs in vivo. α2M is an abundant 
serum inhibitor of many types of proteinases (Sottrup-Jensen and Birkedal-
Hansen, 1989). In addition, thromposbondins can inhibit MMP-2 and -9 activation 
and induce their clearance through scavenger receptor-mediated endocytosis (Bein 
and Simons, 2000). New insight for the regulation of cell surface proteolysis was 
brought by the characterization of a GPI-anchored membrane glycoprotein RECK 
(revision-inducing cysteine-rich protein with kazal motifs), which was shown to 
down regulate MT1-MMP, MMP-2 and MMP-9 function and tumor angiogenesis 
and metastasis (Takahashi et al., 1998; Oh et al., 2001).  
Specific inhibitors, TIMPs are considered to be the key MMP regulators 
locally in tissues. The TIMP family consists of four human TIMPs: TIMP-1, -2, -
3, and –4, which share 30-50% sequence identity (Table 4; Docherty et al., 1985; 
Stetler-Stevenson et al., 1989; Silbiger et al., 1994; Greene et al., 1996). They are 
composed of N- and C-terminal domains, which both are stabilized by three 
disulfide bonds between six conserved cysteine residues (Bode et al., 1999; 
Fernandez-Catalan et al., 1998; Tuuttila et al., 1998). Removal of the C-terminal 
domain has minor effects on the MMP inhibition by the N-terminal domains of 
TIMPs (Murphy et al., 1991; Huang et al., 1997). This larger N-terminal domain 
folds into a β-barrel similar to an oligonucleotide/oligosacharide-binding fold of 
certain DNA-binding proteins (Fig. 2; Tuuttila et al., 1998; Bode et al., 1999). An 
N-terminal extended stretch segment important for MMP inhibition binds to the 
barrel core by two disulfide bridges. The smaller C-terminal domain contains a 
parallel stranded β-hairpin and a β-loop-β motif. α-helixes from the N- and C-
terminal domains form an all-helical center of the protein, and the last acidic C-
terminal residues form a flexible tail on the TIMP surface (Tuuttila et al., 1998). 
All TIMPs can inhibit most MMPs by tight non-covalent binding to their 
active site in a 1:1 stoichiometric ratio (Howard et al., 1991; Gomez et al., 1997). 
MT-MMPs are an exception as TIMP-1 is a poor inhibitor of MT1-, MT2-, MT3-, 
and MT-5-MMP (Will et al. 1996; Shimada et al. 1999). In contrast, MT4- and 
MT6-MMP are also effectively inhibited by TIMP-1 (Kolkenbrock et al. 1999; 
English et al., 2001b). Unlike other TIMPs, TIMP-3 is a good inhibitor of the 
adamalysin-related metalloproteinases (ADAMs; Amour et al., 1998; Hashimoto 
et al., 2001). TIMPs also have differential abilities to form complexes with 
progelatinases through interactions between their C-terminal domains and the C-
terminal hemopexin domains of progelatinases (Table 4; Goldberg et al., 1989; 
Olson et al., 1997; Bigg et al., 1997; Butler et al., 1999). 
TIMPs have been thought to be mainly regulated at the level of gene 
expression. Various cultured cells constitutively express TIMP-2, whereas several  
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growth factors/cytokines and chemicals upregulate the expression of TIMP-1 
(Table 4; Gomez et al., 1997). TIMP-3 expression is induced in cultured cells by 
stimulation with serum, EGF, and TGF-β. Unlike other TIMPs, TIMP-3 is 
insoluble and binds to ECM both in vitro and in vivo. Generally, TIMPs are very 
stable, although they may be inactivated by limited proteolysis by serine 
proteinases like trypsin and elastase (Itoh and Nagase, 1995; Okada et al., 1988).  
Recently, Maquoi et al. (2000) demonstrated that internalization through an MT1-
MMP dependent mechanism and subsequent degradation downregulate TIMP-2 in 
tumor cell cultures.  
Due to their ability to inhibit proteolytic degradation required for cell 
invasion, TIMPs have been indicated as negative regulators of processes like 
angiogenesis and cancer invasion (Gomez et al., 1997). Indeed, TIMP-1 and 
TIMP-2 inhibit endothelial and vascular smooth muscle cell migration (Cheng et 
al., 1998; Fernandez et al., 1999), TIMP-2 reduces melanoma cell invasion, tumor 
growth and angiogenesis in vivo (Valente et al., 1998). Adenovirus-mediated gene 
delivery of TIMP-3 inhibits melanoma cell invasion (Ahonen et al., 1998) and 
overexpression of TIMP-4 inhibits invasion of breast cancer cells in vitro and 
tumor growth and metastasis in vivo (Wang et al., 1997).  On the other hand, 
TIMP-1, -2, and -3 stimulate the growth of several cell types (Henriet et al., 
1999). TIMP-2 can suppress EGF-mediated mitogenic signaling (Hoegy et al., 
2001), and TIMP-3 can induce apoptosis of normal and malignant cells (Ahonen 
et al., 1998; Baker et. al., 1998). Recent data also propose the involvement of 
TIMPs in invasive processes like placental invasion (Henriet et al., 1999).  
 
Table 4.   Tissue inhibitors of metalloproteinases 
Inhibitor Size 
 
Glyco-
sylation 
Solubility ProMMP 
binding 
MT1-MMP 
Inhibition/ 
proMMP-2 
activation 
Gene expression  
upregulated by 
TIMP-1  28 kDa 
 
(184 aa) 
Yes  Soluble  ProMMP-9   No/ no  TGF-β; FGF-2; EGF; 
TNF-α PDGF; IL-1, 
-6; PMA; retinoic 
acid; progesterone; 
oncostatin M 
TIMP-2  21 kDa 
(194 aa) 
No  Soluble  Pro-MMP-2 Yes/ yes  cAMP; LPS; retinoic 
acid; progesterone 
TIMP-3  21-24 
kDa 
(188 aa) 
Yes ECM 
bound 
Pro-MMP-2, 
-9 
Yes/ no  TGF-β; PMA 
TIMP-4  22 kDa 
(195 aa) 
No Soluble  ProMMP-2  Yes/  no  ? 
Modified from (Henriet et al., 1999)  
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MT1-MMP and TIMP-2 in proMMP-2 activation   
The activation of proMMP-2 differs from that of most secreted MMPs, as this 
enzyme cannot be effectively activated by serine proteases (Okada et al., 1990; 
Strongin et al., 1995). ProMMP-2 binds to cell membranes, where its 
processing/activation can be induced by phorbol esters, ConA, β1 integrin 
clustering antibodies, and by cultivation of cells on type I collagen (Brown et al., 
1990; Overall and Sodek, 1990; Brown et al., 1993; Strongin et al., 1993a; Young 
et al., 1995; Yu et al., 1995). MMP inhibitors like 1,10-phenanthroline, EDTA, 
and TIMP-2 inhibit this processing (Brown et al., 1993; Strongin et al., 1993a).  
In the first report of MT1-MMP, Sato et al. (1994) found that transfection of 
MT1-MMP to COS cells induces proteolytic processing of exogenous proMMP-2 
to the active 64-kDa and 62-kDa forms, resembling those seen in PMA or ConA 
treated HT-1080 cells. Strongin et al. (1995) then characterized a receptor 
complex in HT-1080 cells, where the N-terminal inhibitory domain of TIMP-2 
binds to the catalytic center of activated MT1-MMP, while the C-terminal domain 
of TIMP-2 interacts with proMMP-2 (Strongin et al., 1995).  Proteolytic activity 
of adjacent TIMP-free MT1-MMP is required for the processing of the bound 
proMMP-2 to the 64-kDa intermediate form containing N-terminal Leu
67 
(Knäuper, 1998). Studies with catalytically inactive mutants of MMP-2 suggest 
that the activated 62-kDa enzyme with N-terminal Tyr
110 forms by an 
autocatalytic MMP-2 cleavage (Crabbe et al., 1994; Atkinson et al., 1995). The 
stability and concentration dependent activation of the intermediate MMP-2 forms 
in cell culture systems also supports final cell-surface activation through an 
intermolecular cleavage (Overall et al., 2000). While similar MT1-MMP dependent 
two-step activation of MMP-2 occurs also with recombinant proteins in solution 
in the absence of TIMP-2 (Will et al., 1996), the membrane-anchorage of MT1-
MMP is important for this activation in cell culture (Cao et al., 1995).  
TIMP-2 has a dual role in the proposed activation mechanism: at low 
concentrations it induces proMMP-2 activation by promoting the binding of 
proMMP-2 to MT1-MMP, whereas at high concentrations it prevents the 
activation by inhibiting all proteolytic MT1-MMP activity (Strongin et al. 1995). 
In HT-1080 cells proMMP-2 activation is enhanced when recombinant MT1-
MMP and TIMP-2 are expressed in molar ratio from 3:1 to 3:2, while an excess of 
TIMP-2 inhibits the activation (Butler et al., 1998). This enhancing effect requires 
the TIMP-2 C-terminal domain. Similarly, in a cell free system increasing TIMP-
2 concentrations up to molar
  ratio 0.24 of TIMP-2 to MT1-MMP enhances 
proMMP-2 activation by agarose-bound MT1-MMP, while further TIMP-2 
decreases activation (Kinoshita et al., 1998). The characterization of TIMP-2 
knockout mice and the cells derived from them confirmed the dual role of TIMP-2 
on proMMP-2 activation (Caterina et al., 2000; Wang et al., 2000). However, 
studies with modified noninhibitory TIMP-2 and MMP-2 hemopexin domain, as 
well as characterization of the fibroblasts from TIMP-2 deficient mice, have all 
indicated that the first cleavage of proMMP-2 can also occur independently of cell 
surface binding through TIMP-2, whereas the final autocatalytic activation totally  
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depends on this binding (Higashi and Miyazaki, 1999; Overall et al., 2000). In 
contrast, MT2-MMP can mediate proMMP-2 activation by a TIMP-2 independent 
mechanism (Morrison et al. 2001) 
By site-directed mutation analysis the TIMP-2 binding site in proMMP-2 has 
been localized to the junction of hemopexin blades III and IV (Overall et al., 
1999). These blades are localized peripherally away from the catalytic domain in 
the crystal structure of proMMP-2 (Morgunova et al., 1999). The proMMP-2-
binding site in TIMP-2
 has been localized to the 9-aa anionic tail of the C-terminal 
domain (Tuuttila et al., 1998): Deletion of these residues decreases the association 
rate (Willenbrock et al., 1993) and after TIMP-2 binding this C-terminal tail loses 
immunoreactivity, indicating that the tail is buried in the complex (Overall et al., 
2000).  
The major interaction sites for the catalytic
 domain of active MT1-MMPs are 
in the N-terminal domain of TIMP-2 (Fig. 2; Fernandez-Catalan et al., 1998), 
while the C-terminal domain may form stabilizing interactions with the MT1-
MMP hemopexin domain. The edge of TIMP-2, which binds to the MT1-MMP 
active site cleft, is composed of several segments. N-terminal segment Cys
1 to 
Pro
5 binds to the active site of MT1-MMP at the S1, S1', S2', and
 S3' sites, where 
Cys
1 appears to act as fourth ligand for the catalytic zinc and makes a hydrogen 
bond to
  the catalytic glutamic acid (Glu
240) thus replacing an attacking water 
molecule (Bode et al., 1999). In addition, βC-strand connector loop (Ala
65-Cys
72), 
the disulfide bridge between Cys
1 and Cys
72, βE-βF loop (Lys
100-Cys
101), and βG-
βH loop participate in interactions to cover the catalytic cleft (Fernandez-Catalan 
et al., 1998). In the MT1-MMP catalytic domain the "MT-MMP loop" forms a 
surface pocket, with which the long βA-βB-hairpin loop of TIMP-2 interacts 
(Fernandez-Catalan et al., 1998). The Tyr
36 at the end of this AB loop make an 
important binding contribution, because mutations of this single residue 
substantially reduce the rate of TIMP-2 binding to MT1-MMP, but not to other 
MMPs (Butler et al., 1999; Williamson et al., 2001). The
 MT-MMP loop is unique 
to MT1-, MT2-, MT3-, and MT5-MMP, which are all potent proMMP-2 
activators. Accordingly, deletion and point mutations in this loop of MT1-MMP 
affect the kinetics of proMMP-2 activation and TIMP-2 association rate, but have 
no substantial effect on the MT1-MMP activity against peptide substrates and 
macromolecules such as fibrinogen or on the inhibition by TIMP-2 (English et al., 
2001a).  
Specific structural features of proMMP-2 are also likely to affect its 
interactions and activation. The prodomain of MMP-2 has a three-helix fold, 
where the helical part is similar to the corresponding part of proMMP-3, but the 
connecting loops are different (Becker et al., 1995; Morgunova et al., 1999). 
During the activation, the connecting loops of proMMP-2 are sensitive for 
proteolytic cleavage. MT1-MMP cleaves the Asn
66-Leu
67 bond within the loop 
between αI and αII helixes, which contains a unique disulfide bond. In addition, 
the catalytic domain of MMP-2 contains three type II fibronectin repeats, of which 
the third interacts with the prodomain and the first with the blades I and II in the  
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hemopexin domain (Morgunova et al., 1999). The activation of proMMP-2 
mutant lacking the fibronectin repeats is slower than that of the full-length 
enzyme. Interestingly, the soluble mutant MT1-MMP and the corresponding 
mutant with additional deletion of the MT-loop activate this mutant proMMP-2 
lacking the fibronectin repeats with a similar efficiency (English et al., 2001a). 
This suggests that direct interactions between the MT-loop and the fibronectin 
repeats in proMMP-2 might also modulate the activation process.  
The major differences between TIMPs-1, -2, -3, and -4 reside in the exposed 
loop regions and in the flexible C-terminus, which are likely to have important 
roles in the determination of the MT-MMP inhibition specificity as well as in the 
discrimination between proMMP-2 and -9. TIMP-1 has a short AB loop not 
capable of extending
 into the pocket formed by the MT-MMP loop, which has 
been suggested to partly explain
 the lack of MT1-MMP inhibition by TIMP-1 
(Butler et al., 1999). However, TIMP-3 binds MT1-MMP although it also has a 
quite short AB loop. TIMP-4 does not support proMMP2 activation in spite of 
being able to bind to the C-terminal hemopexin domain of MMP-2 (Bigg et al., 
1997) and efficiently inhibit MT1-MMP (Bigg et al., 2001).   
Cell migration 
Cell migration is a recurring phenomenon in all morphogenic processes during the 
embryonic development (Zagris, 2001). In the adults, physiological migration 
processes also include trophoblast invasion and invasive migration of neutrophils 
and macrophages (Mignatti and Rifkin, 2000). In many other adult cells the 
capacity for cell movement can be activated by wounding or trauma or by 
malignant transformation.  
Cell migration is accomplished by propulsive forces transferred from ECM to 
cytoskeleton through repeated cycles of adhesion, detachment and proteolysis 
(Lauffenburger and Horwitz, 1996; Mitchison and Cramer, 1996). Binding of 
ligands to specific cell surface integrins modulates the integrin activity and 
induces integrin clustering to focal contacts at the edges of cells. The cytoplasmic 
tails of integrins interact with cytoskeletal multiprotein complexes that link the 
focal contacts to actin filaments and intracellular signaling pathways. These 
interactions regulate the activity of Rho family of small GTPases such as Cdc42, 
Rac, and Rho, which are critical for the assembly of actin cytoskeletal 
components to form membrane ruffles, filopodia, and lamellipodia (Mitchison and 
Cramer, 1996; Sander and Collard, 1999; Evers et al., 2000). Cdc42 is a key 
regulator of filopodia, which are thin cylindrical projections with bundle of long 
actin filaments stabilized by actin binding proteins. Rac regulates the organization 
of lamellipodia that are broad, thin protrusive sheets at the leading edge of 
migrating cells. Rho is more important for the formation of actin stress fibers and 
for focal contact assembly. Forward movement of the cell results from adhesive 
traction by focal contacts and actin filament contraction. As the cell moves 
forward the focal contacts move in a retrograde fashion, but the magnitude of  
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traction is greater than the reward pull through the adhesion complexes. New 
protrusions and focal contacts form continuously at the leading edge 
(Lauffenburger and Horwitz, 1996). At the cell rear focal adhesions detach from 
matrix and filament contraction pulls the rear forward. Here the magnitude of 
traction is less than contraction. 
 The direction of cell migration is affected by chemoattractants and by the 
generation of preferred adhesive interactions. Chemoattractants include cytokines 
and growth factors such as TGF-β, EGF, FGF, and VEGF, and matrix fragments, 
which are recognized by adhesion receptors. Proteolytic enzymes and their 
inhibitors may modulate cell migration at least by: 1) clearing the restricting 
ECM, 2) remodeling ECM components or cell adhesion molecules to modify 
affinity and dynamics of cell-ECM interaction, for example, cryptic Arg-Gly-Asp 
(RGD) sequences exposed from fibrillar collagen by proteolysis
 may modify the 
substrate to become suitable for migration (Davis, 1992), 3) mobilizing and 
activating or inactivating growth factors, cytokines, and chemokines  (Imai et al., 
1997;  Fowlkes et al., 1994; McQuibban et al., 2001; Whitelock et al., 1996), 4) 
generating regulatory fragments such as endostatin, (Sasaki et al., 1998; 
Wickström et al., 2001), angiostatin (Cornelius et al., 1998), and sites in laminin-5 
α3 chain that may direct the path in front of invading cells (Giannelli et al., 1997; 
Koshikawa et al., 2000). 
Pericellular proteolysis 
In tissues, considerable molar excess of proteinase inhibitors derived either from 
plasma or secreted by the tissue cells protects the surrounding ECM from 
degradation. Focal proteolytic activity can be achieved when proteinases are 
compartmentalized and activated in the immediate pericellular environment where 
proteinase inhibitors have limited access (Sternlicht and Werb, 2001). Indeed, 
localizing proteases and their activators to the plasma membrane and special 
membrane domains via a transmembrane domain or binding to cell surface 
receptors has emerged as an important mechanism for the generation of 
biologically active proteinases that mediate variety of cellular functions (Werb, 
1997; Sternlicht and Werb, 2001).  
The cell surface enzymes characterized in pericellular proteolysis include 
MMPs, ADAMs, and serine proteases including plasmin and uPA/uPA receptor 
system and type II transmembrane serine proteinases (TTSPs) (Werb, 1997; 
Blobel, 1997; Chapman, 1997; Hooper et al., 2001). All these proteinases have 
multidomain structures that provide them with capacity to interact with multiple 
partners in many cases on both sides of plasma membrane and in intracellular 
compartments. Therefore, they may be involved in multiple cellular pathways.  
Interplay between proteolysis, adhesion, and signaling  
During cell invasive and morphogenic processes, the cell surface association of  
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proteolytic activity has several advantages. First, the proteinase-inhibitor balance 
can be finely turned to favor pericellular proteolysis, while the surrounding tissue 
is protected by inhibitors (see above). As a result, sufficient matrix can be 
degraded to allow forward movement while an attachment surface is left for 
propulsion (Hiraoka et al., 1998; Hotary et al., 2000; Werb, 1997). Secondly, cell 
surface-associated proteinases may specifically interact with cell surface signaling 
receptors or their pericellular ligands, as well as with the cytoplasmic signaling 
complexes, and in this manner function as key regulators of signaling events. 
Thirdly, proteolytic enzymes may interact and cooperate with adhesion receptors 
to control continuous cell adhesion and detachment events required for cell 
movement. The ADAMs that are thought to be involved in fertilization, 
development, inflammation, and angiogenesis (Black et al., 1997; Blobel, 1997) 
have been implicated in the proteolysis of ECM components and cell surface 
proteins including Notch and TNF-α, in RGD-dependent and -independent 
interactions with integrins, and signaling via interactions of their cytoplasmic 
domains (Black and White, 1998). The uPA/uPA receptor system, on the other 
hand, is an example of complex coordinated regulation of protease and adhesion 
systems to promote cell migration. While uPAR is the major binding site for uPA, 
the plasminogen activator generating active plasmin (Chapman, 1997), uPAR may 
also serve as a high affinity receptor for vitronectin (Wei et al., 1994). Based on 
the observation that macrophage adhesion is affected by uPA binding to uPAR 
independently of the proteolytic activity of uPA, uPAR has been suggested to 
transduce signals to cytoskeleton that regulate cell adhesion (Gyetko et al., 1994). 
Later it was found that uPAR could form complexes with β1-integrins and 
caveolin (Wei et al., 1996) while integrin-dependent signaling events regulate the 
expression of uPAR in T-cells (Bianchi et al., 1996). Recent data also suggest that 
cell adhesion and migration may be modulated by interactions of MMPs with β1- 
and β3-integrins (Brooks et al., 1996; Deryugina et al., 2001a; Dumin et al., 2001) 
and other cell surface components, such as CD44 (Kajita et al., 2001), tissue 
transglutaminase (Belkin et al., 2001), and melanoma chondroitin sulphate 
proteoglycan (Iida et al., 2001). Like uPAR, MT1-MMP has also been localized to 
caveolin-rich lipid rafts, caveolaes (Annabi et al., 2001a; Puyraimond et al., 
2001), where distinct interactions and signaling events may occur. 
Proteolytic cascades 
Increasing evidence points to a cross talk between different proteolytic 
systems at the cell surface. The uPA/uPA receptor pathway has an important role 
in the activation of many soluble MMPs (Carmeliet et al., 1997; Mazzieri et al., 
1997). Once activated by furin-like serine proteinases, MT-MMPs co-operating 
with TIMPs may also contribute to the activation of many other proteinases 
(Knäuper, 1998). Furthermore, various secreted serine proteinases including 
thrombin and plasmin may modulate MT1-MMP/TIMP/MMP-2 activation 
cascades (Schwartz et al., 1998; Lafleur et al., 2001a; Lafleur et al., 2001b; Monea 
et al. 2002). A member of TTSP family, MT-SP1 can activate pro-uPA on the cell  
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surface (Takeuchi et al., 2000). One potentially important feature of these cell 
surface cascades is that they may allow amplification of the pericellular 
degradative processes, if one cell surface proteinase can activate many soluble 
enzymes. MT-MMPs, uPA/uPA receptor as well as TTSPs have all been localized 
to the leading edges of migrating cells, which with the substantial similarities 
between their regulation and interactions supports their cooperative and/or 
compensating function at the cell surface. The set of proteolytic cascades involved 
in invasive and degradative processes may depend on, for example, the proteinase 
expression pattern of a given cell type or the nature of the activating signals. 
Role of MT1-MMP in cell migration 
MT1-MMP promotes invasive phenotype of normal and neoplastic cells of 
fibroblastic, endothelial, and epithelial origin. Laminin-5 cleavage by MT1-MMP 
and MMP-2 may be one mechanism that triggers migration of cells on epithelial 
basement membranes (Giannelli et al., 1997;  Koshikawa et al., 2000; Seftor et al., 
2001). Interestingly, the small GTPase Rac1, which regulates the dynamics of 
actin cytoskeleton during cell migration, induces MT1-MMP expression and 
clustering, proMMP-2 activation, and HT-1080 cell invasion on fibrillar collagen 
(Zhuge and Xu, 2001; Itoh et al., 2001). During cell migration the coordinated 
interplay between MT1-MMP mediated proteolysis and cell adhesion appears to 
involve complex regulatory mechanisms. While integrin-dependent signaling 
events may modulate MT1-MMP expression in response to type I collagen (Haas 
and Madri, 1999), MT1-MMP mediated processing of integrin pro-αV  chain 
stimulates migration of MCF-7 breast carcinoma cells on vitronectin. This 
processing also enhances tyrosine phosphorylation of FAK, without affecting 
RGD-ligand binding by the αVβ3 integrin (Deryugina et al., 2001a; Ratnikov et al., 
2001). In addition, MT1-MMP may induce tumor cell migration by cleaving 
CD44, the main cell surface receptor for hyaluronan (Kajita et al., 2001). 
Furthermore, MT1-MMP has been reported to induce activation of intracellular 
signaling cascades involving extracellular signal-regulated protein kinase (ERK) 
by a mechanism that is dependent on both the catalytic activity and the 
cytoplasmic domain, and correlates with increased cell invasion through Matrigel 
(Gingras et al., 2001).  
Biological roles of MT1-MMP 
During mouse embryogenesis, MT1-MMP is expressed at high levels in 
developing blood vessels, bones, and kidney as well as in osteocartilaginous and 
musculotendinous tissues (Kinoh et al., 1996; Apte et al., 1997). Different 
distribution of mRNAs for the six MT-MMPs in human tissues (Table 3) indicate 
the differential tissue and cell type specific regulation of their gene expression. 
The high level of MT3-, MT4-, and MT5-MMP expression in brain suggests 
specific roles in the central nervous system, while expression of MT4- and MT6- 
 33
MMP in leukocytes suggests roles in the inflammatory response.  
In the tissues of TIMP-2 and MT1-MMP-deficient mice proMMP-2 
activation is impaired indicating a functional link between these two enzymes and 
the TIMP-2 mediated receptor system in vivo (Caterina et al., 2000; Wang et al., 
2000; Zhou et al., 2000). However, MMP-2 and TIMP-2 -deficient mice display 
subtle phenotypes, whereas MT1-MMP deficiency causes severe defects in 
skeletal and extraskeletal connective tissue metabolism and cartilage angiogenesis 
(Holmbeck et al., 1999; Zhou et al., 2000) suggesting that the severe phenotype in 
MT1-MMP-deficient mice is not primarily a consequence of impaired proMMP-2 
activation. 
Angiogenesis 
Angiogenesis, i.e. formation of new blood vessels from the existing ones is 
essential for tissue development and repair, and tumor growth. Angiogenesis may 
be initiated when the balance turns to the dominance of positive angiogenesis 
factors by the induction of positive factors such as VEGF and FGF-2, and/or loss 
of negative regulation (“angiogenic switch”; Hanahan and Folkman, 1996; 
Pepper, 2001). In most mature tissues, on the other hand, predominating negative 
regulation through for example, proteinase inhibitors, thrombospondins, and 
interactions with various ECM components or their proteolytic fragments are 
important for maintaining endothelial quiescence. The activation of angiogenesis 
involves coordinated alterations in cell-cell and cell-ECM interactions and cell 
phenotype accompanied by alterations of dynamic signal transduction cascades 
downstream of growth factor and adhesion receptors (Hanahan and Folkman, 
1996; Stromblad and Cheresh, 1996). These alterations lead to increased vascular 
permeability, extravascular fibrin deposition, and the induction and activation of 
MMP and plasminogen activator (PA)/plasmin cascades (Carmeliet and Collen, 
1998; Pepper, 2001). This is followed by localized proteolytic degradation of the 
sub-endothelial basement membrane and the proliferation and migration of 
activated endothelial cells into fibrin rich matrix to form a capillary bud and then 
a capillary tube. During the maturation of newly formed blood vessels the 
regulatory balance has to be restored to favor basement membrane assembly and 
endothelial cell differentiation.    
In MT1-MMP deficient mice angiogenesis of cartilage is defective 
(Holmbeck et al., 1999; Zhou et al., 2000), and in corneal angiogenesis assay 
these mice do not have angiogenic response to implanted FGF-2 (Zhou et al., 
2000). In addition, angiogenic stimuli selectively upregulate MT1-MMP 
expression in endothelial cells in vitro suggesting a role for MT1-MMP during 
these processes (Haas and Madri, 1999). By virtue of the capacities of MT1-MMP 
to activate proMMP-2 and directly degrade various substrates, it may be involved 
in several distinct ECM remodeling events during angiogenesis. Substantial 
evidence supports the involvement of MMP-2 activity in angiogenesis. For 
example, an increase in MMP-2 activity is associated with angiogenic phenotype  
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of cells in rat Swarm chondosarcoma model, while antisense MMP-2 
oligonucleotides inhibit angiogenesis and tumor growth in this model (Fang et al., 
2000). On the other hand, endogenous angiogenesis inhibitors like 
thrombospondins and endostatin (a proteolytic fragment of collagen XVIII) have 
been reported to repress MMP-2 activity or activation (Bein and Simons 2000; 
Kim et al. 2000). In addition, αvβ3 binds the intermediate form of MMP-2 through 
the C-terminal hemopexin-like domain (PEX) and facilitates its maturation on the 
cell surface (Brooks et al., 1996; Deryugina et al., 2001a). Accordingly, PEX 
inhibits angiogenesis when used as a recombinant protein or when delivered by a 
viral vector both in vitro and in vivo models (Brooks et al., 1996; Brooks et al., 
1998; Pfeifer et al., 2000). Finally, in MMP-2 deficient mice, tumor induced 
angiogenesis is markedly reduced in a dorsal air sac assay with B16-BL6 
melanoma cells (Itoh et al. 1998).  
Until recently, the PA/plasmin system has been considered to be responsible 
for the major fibrinolytic activity of cells. While experiments with PA and 
plasminogen deficient mice have shown the essential role of these proteinases for 
the fibrinolysis by several types of cells including keratinocytes, smooth muscle 
cells, and inflammatory cells, these mice do not exhibit clear angiogenic 
phenotypes (Carmeliet et al., 1994; Romer et al., 1996; Bugge et al., 1996; 
Carmeliet et al., 1997; Carmeliet and Collen, 1998). Therefore, endothelial cells 
have been suggested to invade fibrin rich matrixes in plasmin independent 
manner. Indeed, Hiraoka et al. (Hiraoka et al., 1998) found that in an ex vivo 
model tissues from PA and plasminogen deficient mice efficiently neovascularize 
to surrounding fibrin gel. MMP inhibitors, but not serine, cysteine, or aspartate 
proteinase inhibitors prevent the neovessel formation in vivo and in vitro and the 
invasion of isolated endothelial cells to fibrin gel. Of the recombinant MMPs 
(MMP-1, -2, -3, and MT1-MMP) soluble truncated MT1-MMP has the highest 
fibrinolytic activity, whereas fibrinolysis by membrane anchored MT1-MMP is 
critical for the MDCK cell invasion to fibrin gel (Hiraoka et al., 1998). These 
results suggest that endothelial cells can use membrane-bound MMPs such as 
MT1-MMP to invade fibrin rich matrix. Interestingly, MMP-9 can also act as a 
fibrinolytic enzyme and prevent fibrin accumulation in glomeruli (Lelongt et al., 
2001).    
Bone development 
Bone development proceeds either by intramembranous or endochondral 
ossification. Axial skeleton develops through endochondral ossification (Olsen et 
al., 2000). Mesenchymal cells first aggregate to form bone anlagen, where the 
peripheral cells begin to flatten to form perichondrium. The cartilage elongates 
and expands by proliferation of
 chondrocytes and cartilage matrix deposition.
 In 
the central region, chondrocytes differentiate to hypertrophic
 chondrocytes with 
enlarged cytoplasms, which then exit cell cycle and synthesize bone matrix. These 
hypertrophic chondrocytes secrete angiogenic factors, which induce vascular  
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invasion and invasion of chondroclasts, osteoblasts and osteoclasts from the 
perichondrium. These invading cells express receptors for angiogenic factors and 
MMP-9 and MT1-MMP (Vu et al., 1998; Colnot and Helms, 2001). In the 
ossification center, MMP-13 is induced and the hypertrophic cartilage matrix is 
degraded.
  The hypertrophic chondrocytes then die, osteoblasts
  replace the 
disappearing cartilage with trabecular bone, and
 bone marrow is formed. In the
 
perichondrium osteoblasts form compact bone around the middle
  portion 
(diaphysis) of the cartilage, so that the primary ossification
 center stays inside a 
bone tube. Secondary ossification
 centers form at one or
 both ends (epiphyses) of 
the bone. As a result a plate of cartilage (growth plate)
 is left between epiphysis 
and diaphysis. In the growth plate,
  series of chondrocyte proliferation, 
hypertrophy, and apoptosis
 lead to longitudinal growth of long bones,
 coordinately 
with growth
 of the epiphysis and radial growth of the diaphysis. By contrast, some 
craniofacial bones develop by intramembranous ossification, where osteoblasts 
directly deposit bone matrix to replace the cartilage matrix, and the bone 
remodeling is associated with bone vasculation. In both cases, dynamic bone 
remodeling continues through ECM deposition and resorption by the co-operative 
action of osteoblasts and osteoclasts. 
Mice deficient of either MT1-MMP or MMP-9 show bone malformation 
phenotypes. In MMP-9 deficient mice, the defects in epiphyseal ossification lead 
to subtle shortening of the bones (Vu et al., 1998), whereas in MT1-MMP 
deficient mice the craniofacial, axial, and appendicular skeletons are severely 
affected (Holmbeck et al., 1999; Zhou et al., 2000). Severe connective tissue 
disorders in MT1-MMP deficient mice include dwarfism, skeletal dysplasia, 
osteopenia, soft tissues fibrosis, arthritis, and early death. Defective vascular 
invasion of cartilage leads to enlargement of hypertrophic zones of growth plates 
and impaired formation of ossification centers in long bones. Normal endothelial 
cells, osteoclasts and osteoblasts express MT1-MMP both in vitro and in vivo 
(Sato et al., 1997; Haas and Madri, 1999). Therefore, MT1-MMP may have 
important roles in the invasion of any of these cells to hypertrophic cartilage. In 
migrating osteoclasts, MT1-MMP is focused to the lamellipodia (Sato et al., 
1997). MMP activity is required for the migration of osteoclasts in developing 
marrow cavity (Blavier and Delaisse, 1995), but the distinct roles of MT1-MMP 
and MMP-9 in this migration are not well understood.  
Bone resorption and osteoclastic activity are increased in MT1-MMP 
deficient mice indicating that MT1-MMP is not critical for bone degradation by 
osteoclasts, an activity that has been primarily associated for acidic proteinases of 
cathepsin family (Hall and Chambers, 1996). Rather, the osteopenia correlates 
with the increased osteoclastic bone resorption and impaired function of 
osteoblasts. Chondrocyte proliferation is also reduced in the growth plates (Zhou 
et al., 2000). On the other hand, skin fibroblasts and stromal marrow cells from 
MT1-MMP deficient mice cannot degrade type I collagen matrix suggesting an 
indispensable role for MT1-MMP activity in stromal collagen remodeling 
(Holmbeck et al., 1999). The bone resorption was suggested to be a compensatory  
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response for abundant periskeletal fibrosis resulting from the inability of soft 
tissue cells to remodel surrounding collagenous matrix (Holmbeck et al., 1999). 
Interestingly, the growth of MMP-2 knockout mice is also delayed (Itoh et al. 
1997). In humans, inactivating mutations of MMP-2 cause a multisendric 
osteolysis and arthritis syndrome with similarities to the phenotype of MT1-MMP 
knockout mice (Martignetti et al. 2001). Therefore, the osteolytic phenotypes 
could result from imbalance between the breakdown and synthesis of stromal 
and/or bone ECM near bone/soft tissue interfaces, which would cause impaired 
function of osteoblasts and osteoclasts. Finally, impaired MT1-MMP dependent 
removal of collagenous uncalcified cartilage primordia interfere with 
intramembranous bone formation and suture closure.   
In MMP-9 deficient mice, the hypertrophic chondrocytes develop normally, 
but their apoptosis as well as epiphyseal vasculation and ossification are delayed, 
resulting in lengthening of the growth plate (Vu et al., 1998). Interestingly, the 
inhibition of VEGF signaling by injection of soluble VEGFR1 receptor
 (Flt-1-IgG 
fusion protein) in mice inhibits vascular invasion and recruitment of 
chondroclasts, osteoblasts, and osteoclasts into hypertrophic cartilage and results 
in a bone phenotype similar with the MMP-9 knockout (Engsig et al., 2000; 
Gerber et al., 1999). Furthermore, in a transgenic RIP Tag mice model of SV40 T 
antigen (Tag) induced pancreatic beta cell carcinogenesis, angiogenesis appears to 
depend on the mobilization of VEGF from the ECM stores by MMP-9. In this 
model, the “angiogenic switch” is not associated with transcriptional upregulation 
of VEGF, its receptor or FGF-2, whereas in RIPTag X MMP-9-deficient double 
transgenic mice angiogenesis and tumor growth are inhibited (Bergers et al., 
2000). MMP-2 deficiency does not affect angiogenesis in this model. Therefore, 
MMP-9 may be important for recruitment of endothelial cells and other cell types 
invading to ossification centers by mobilizing VEGF from hypertrophic ECM 
(Sternlicht and Werb, 2001).  
Cancer  
Cancer invasion and metastasis depend on a series of proteolytic steps. During 
initial invasion into the stromal tissue cancer cells traverse the basement 
membrane by a process depending on proteinases that can degrade and remodel 
basement membrane components (McCawley and Matrisian, 2001; Stetler-
Stevenson and Yu, 2001). Continued cancer cell invasion is facilitated
  by the 
degradation of the surrounding stromal matrix,
 where tumor tissue substitutes the 
normal host tissue. Formation of solid tumor also requires angiogenesis to provide 
blood supply into the growing tumor tissue (Folkman, 1995).
 During metastasis a 
tumor cell dissociates from the primary tumor, invades the surrounding ECM, 
including interstitial stroma and basement membranes, enters the vascular or 
lymphatic space (intravasation), adheres to the endothelium at distant sites, 
egresses from the vasculature (extravasation) into the surrounding tissue, and 
proliferates to form a secondary tumor (metastasis) (Mignatti and Rifkin, 1993).   
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Numerous studies have described the overexpression of various proteinases 
including serine, metallo-, cysteine, and aspartic proteinases by invasive and 
metastatic tumor cells or stromal cells (Sloane, 1990; Rochefort et al., 1990; Pyke 
et al. 1992, 1993; Johnsen et al. 1998; Stetler-Stevenson and Yu, 2001; Sternlicht 
and Werb). The candidates most often implicated in invasion and metastasis are 
uPA and various MMPs (Johnsen et al. 1998; Stetler-Stevenson and Yu, 2001). 
However, invasive growth involves concerted action of different proteinases and 
proteinase cascades, and the set of proteinases used may vary in cancers 
originating from different tissues. Accordingly, MMP and serine proteinase 
inhibitors negatively regulate tumor invasiveness in many in vitro and in vivo 
models (Mignatti et al., 1986; Khokha et al., 1989; Koop et al., 1994; Martin et 
al., 1996; Sternlicht and Werb, 2001;). However, TIMP-1 is often overexpressed 
in colon cancer, and enhanced expression of TIMP-2 in the stroma of breast 
carcinomas correlates with tumor recurrence (Lu et al., 1991; Visscher et al., 
1994). In addition, reduction of MMP-9 in mice leads to decreased angiostatin 
synthesis and consequent increased tumor growth and vascularization, while high 
MMP-9 expression causes a reduction in tumor vascularization (Pozzi et al., 2002; 
Pozzi et al., 2000). These results suggest that even in cancer the extracellular 
proteolysis has to be tightly regulated to allow cancer and endothelial cells to 
grow and invade. Indeed, many of the proteolytic mechanisms involved in cancer 
cell invasion are apparently similar to those used during cell migration in 
physiological processes. On the other hand, recent studies with transgenic mice 
lacking or overexpressing a single MMP gene also support a role for MMPs, e.g. 
MMP-3 and MMP-7, already during cancer initiation (Sternlicht and Werb, 2001).  
Cancer cells recruit macrophages and stromal cells surrounding the invading 
front of metastazing tumor to secrete proteinases like uPA and proMMP-2 (Pyke 
et al., 1992; Pyke et al., 1993). If the cancer cells express receptors and activators 
like uPAR and MT1-MMP, the proteolytic potential produced by stromal cells can 
be focused on the cancer cell surface. Indeed, several forms of cancer, including 
those of gastric, lung, breast, ovarian, colon, cervical, urothelial, thyroid, 
hepatocellular, bladder, and pancreatic origin, show high MT1-MMP expression, 
either by cancer cells themselves or by stromal cells (Nomura et al., 1995; Okada 
et al., 1995; Polette et al., 1996; Tokuraku et al., 1995; Yamamoto et al., 1996). 
MT1-MMP expression levels also correlate with MMP-2 activation and the 
malignancy and invasiveness of the tumor (Yamamoto et al., 1996), and MT1-
MMP expression enhances metastatic activity in an experimental metastasis assay 
(Tsunezuka et al., 1996). In transgenic mice MT1-MMP overexpression induces 
mammary gland abnormalities and adenocarcinoma (Ha et al., 2001). Cancer cells 
from different tissues may use distinct MT-MMPs. Indeed, MT3-MMP is 
expressed in several cultured cancer cell lines (Takino et al., 1995), MT4-MMP is 
expressed in various breast carcinomas and breast cancer cell lines (Puente et al., 
1996), and high levels of MT5-MMP are detectable in brain tumors (Llano et al., 
1999).  
Recently, new insights
  into the profiles of gene expression during tumor  
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invasion have come from gene expression microarrays. Both MT1-MMP and 
MMP-2 are highly expressed in invasive pancreatic cancer tissues (Iacobuzio-
Donahue et al., 2002). Further characterization of such tissues have indicated that 
MT1-MMP is overexpressed especially in the neoplastic epithelium, whereas 
MMP-2 mRNA expression is induced within the stromal response. The expression 
of MMP-1, -2, -9, and MT1-MMP and also of laminin-5 γ2 chain is significantly 
increased in aggressive compared with poorly aggressive melanoma cells (Seftor 
et al. 2001). MT1-MMP expression is also induced in metastatic colorectal cancer 
as compared to primary cancers and normal colorectal epithelium (Saha et al. 
2001).   
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Aims of the present study 
The activities of MMPs are regulated at multiple levels including gene expression, 
secretion and binding to the cell surface or ECM, proteolytic activation, and 
inhibition by TIMPs to achieve targeted ECM remodeling during multiple 
physiologic processes. Dysregulated MMP activity, in contrast, is associated with 
various pathological conditions. The discovery of membrane-bound MMPs, which 
may both remodel ECM and cell surface proteins, and also participate in 
pericellular cascades to activate other MMPs revealed a new field for cellular 
regulation of MMP activity. In the current work the aim was to find answers to the 
question: How is MT1-MMP activity regulated during cell migration and 
invasion? We first characterized the regulation at the level of gene expression, and 
I then concentrated on characterizing posttranslational mechanisms of the 
regulation. The specific questions raised during the work include the following: 
 
1) How do cell growth modulating factors regulate MT1-MMP and TIMP-2 at 
the levels of mRNA and protein expression, and how do their expression 
correlate with proMMP-2 activation? 
2) Does proteolytic processing of MT1-MMP play a role in the regulation of 
its activity? 
3) What kind of protein-protein interactions regulate the functions and 
distribution of MT1-MMP, and do the MT1-MMP molecules interact with 
each other to form oligomeric complexes? 
4)  What is the role of the cytoplasmic domain in the regulation of MT1-MMP 
by membrane trafficking and in the targeting of MT1-MMP activity at the 
cell surface?  
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Materials and methods 
Growth factors, chemicals, and enzymes.  
Phorbol 12-myristate 13-acetate (PMA), the calcium ionophore A23187 
(calcimycin), ionomycin, dexamethasone, cycloheximide, actinomycin D, ConA, 
human recombinant EGF, thapsigargin, and human type I collagen were 
purchased from Sigma Chemical Co. (St. Louis, MO). Human recombinant IL-1β 
and TNF-α were obtained from Boehringer Mannheim GmbH (Mannheim, 
Germany). Human recombinant bFGF (FGF-2) was kindly provided by Dr. Olli 
Saksela, Helsinki, Finland. Human platelet derived TGF-β was from R&D 
Systems (Minneapolis, MN). MMP-2 and TIMP-2 were from Chemicon Co. 
(Temecula, CA). Cyclic peptide inhibitor CTTHWGFTLC, which inhibits 
specifically gelatinases (Koivunen et al., 1999), was obtained from Dr. E. 
Koivunen Helsinki, Finland. The MMP inhibitor with broad inhibitory activity, 
BB-3103, was from British Biotech Pharmaceuticals Ltd (Oxford, U.K.).   
Cell culture and treatments 
The following table indicates the cell lines used and their ATCC (American Type 
Culture Collection, Rockville, MD) identification numbers. All cells were grown 
in Eagle's minimal essential medium (MEM) containing 10% heat-inactivated 
fetal calf serum (GIBCO), 100 IU/ml penicillin, and 50 µg/ml streptomycin. The 
cultures were incubated at 37°C in a humidified 5% CO2 atmosphere until 
confluent. They were then rinsed twice with serum-free medium and incubated 
under serum-free conditions for 6 h. For analyses, cells were treated with PMA (4-
40 nM), BB-3103 (1-10 µM), ionomycin (500 nM), thapsigargin (500 nM), TNF-
α (20 ng/ml), IL-1β (2 U/ml), Con A (50 µg/ml), EGF (30 ng/ml), FGF-2 (30 
ng/ml), TGF-β (10 ng/ml), A23187 (500 nM), cycloheximide (10 µg/ml) and 
dexamethasone (1 µM) under serum free conditions for 24 h or as indicated.  
Name Description  Used  in     
Bowes human  melanoma  cells  IV 
CCL-137  human embryonic lung fibroblasts, ATCC  I, II, III    
 CCL-127 
CHO  Chinese hamster ovary epithelial cells,  V 
 ATCC  CCL-61 
COS-7  African green monkey kidney epithelial  I, V  
  cells, SV40 transformed, ATCC CRL-1651 
HEK293  Human embryonic kidney cells  V 
HT-1080   Human fibrosarcoma cells, ATCC CCL-121  I, II, III, V 
MDCK  Madin-Darby canine kidney epithelial cells  V 
VA-13  SV-40 transformed human lung fibroblasts,  III    
 ATCC  CCL-75.1  
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Antibodies 
The antibodies used in the experiments have been listed in the following table. 
Polyclonal antibodies to MT1-MMP were raised in rabbits and affinity purified as 
described in detail in the original articles (I, II). The immunogens used were: a 
bacterially generated recombinant fusion protein of Schistosoma japonicum 
glutathione S-transferase and amino acid residues 260 to 484 of MT1-MMP (Ab-
1), a 26 amino acid long synthetic peptide corresponding to the C-terminal 
cytoplasmic domain of MT1-MMP (Ab-2) and a 24 amino acid long synthetic 
peptide corresponding to the amino acids 155-177 of MT1-MMP (Ab-3).  
 
Name Immunogen  Use    Reference 
Rabbit: 
Ab-1  GST/MT1-MMP(260-484)   IB, IP, IF (I,II, IV)    I    
   fusion protein     
Ab-2  MT1-MMP peptide 557-582  IB, IP (I,II, III,IV)    I 
Ab-3  MT1-MMP peptide 155-177  IB, IP, IF (III, IV, V)   IV 
Ab815  MT1-MMP (hinge)  IB, IP, IF (III)    Chemicon   
 TIMP-2  IB    Chemicon 
  GST  IB, (III)     Upstate   Biotechnology 
Goat: 
Ab6613  GST  IB, IF (III)    Abcam 
Mouse: 
Ab92  GST  IB, IF (III)    Abcam 
Northern hybridization and RNAse protection 
RNA isolation and Northern blotting: RNA was purified by pelleting a guanidine 
thiocyanate-N-laurylsarcosyl cell lysate through a CsCl cushion. Total RNA (15 
µg) was fractioned by formaldehyde-agarose gel electrophoresis and transferred to 
a Zeta probe membrane (Bio-Rad, Richmond, CA) and immobilized by UV 
crosslinking. The membranes were hybridized to MT1-MMP and TIMP-2 cDNA 
probes labeled with [32P]dCTP (Amersham-Pharmacia Biotech, Upsala, Sweden)  
using random priming kit (Amersham-Pharmacia Biotech). The signal intensities 
were quantitated by phosphoimager analysis (Fuji Photo Film Co., Tokyo, Japan). 
Ribonuclease protection analyses were carried out using Direct Protect kit 
(Ambion Inc., Austin, TX) and [32P]UTP (Amersham) labeled cRNA probe 
complementary to a 251 bp fragment of MT1-MMP cDNA (bases 852-1102).  
Expression constructs 
Amplification of MT1-MMP cDNA by PCR and isolation of cDNA clones has 
been described in detail in the original article I. An expression plasmid MTpc3SE 
containing bases 1-2369 of MT-MMP-1 cDNA under transcriptional control by 
the CMV promoter was constructed on pcDNA3 vector (Invitrogen, San Diego  
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CA). All the listed deletion and mutation constructs were generated from 
MTpc3SE by PCR mediated mutagenesis as described in the respective articles. 
  
 Name    (Tag/) MT1-MMP amino acids  Reference (Used in) 
 
MTpc3SE/wt  MT1-MMP 1-582  I, IV (I, II, III, IV, V) 
E240A  MT1-MMP 1-582,   Valtanen et al 2000,IV (IV) 
    inactivating E240A point mutation 
∆ ∆ ∆ ∆577  MT1-MMP 1-577  IV, (IV) 
∆ ∆ ∆ ∆573  MT1-MMP 1-573    IV, (IV) 
∆ ∆ ∆ ∆567   MT1-MMP 1-567  IV, (IV) 
∆ ∆ ∆ ∆TM   MT1-MMP 1-538  IV (II, IV,) 
∆ ∆ ∆ ∆Cyt   MT1-MMP 1-564  Pei et al. 1996 (III, V) 
∆ ∆ ∆ ∆Cat   GST/MT1-MMP 296-582   III (III) 
∆ ∆ ∆ ∆Cat/Pex  GST/MT1-MMP 438-582  III (III) 
TM/Cyt   HA/MT1-MMP 525-582  III (III)       
Transfection of cells 
Cells were cultured on a six-well plate to reach 50-80 % confluence and 
transfected using 2 µg of plasmid DNA and 5 µl of FuGENE 6 -transfection 
reagent for each transfection according to the manufacturer’s instructions 
(Boehringer Mannheim, Mannheim, Germany). Stable transfectants were selected 
with 0.5-1.2 mg/ml G418 (Gibco-BRL) in complete medium. Expression of the 
recombinant MT1-MMPs by the transfected cell clones was analyzed by 
immunoblotting and Northern blotting.  
SDS-PAGE and immunoblotting  
SDS-PAGE of was carried out using 4-15% gradient or 7.5% and 10% standard 
polyacrylamide gels  (Bio-Rad Co., Richmond, VA). The proteins were then 
transferred to nitrocellulose membranes, which were saturated with 5% milk in 
PBS/Triton X-100 (0.5%) and incubated with primary antibodies in 50 mM Tris-
HCl buffer, pH 8.5 containing 500 mM NaCl, 0.1 % Tween 20 and 0.1 % bovine 
serum albumin. After several washes with the same buffer the bound antibodies 
were detected using biotinylated antimouse or antirabbit antibodies and 
peroxidase-conjugated streptavidin (Dakopatts, Copenhagen, Denmark) and 
enhanced chemiluminescence Western blotting detection system (Amersham). 
Gelatin zymography and reverse zymography  
To analyze the gelatinolytic proteins, aliquots of cell conditioned medium, cell 
membrane extracts or immunoprecipitated MT1-MMP immune complexes were  
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analyzed by gelatin zymography essentially as described (Lohi et al. 1995). 
Samples were dissolved in non-reducing Laemmli sample buffer and separated by 
SDS-PAGE using10% polyacrylamide gels containing 1 mg/ml of gelatin. After 
electrophoresis the gels were washed twice with 50 mM Tris-HCl, pH 7.6, 
containing 5 mM CaCl2, 1 µM ZnCl2, 2.5% Triton X-100 (v/v) for 15 min to 
remove SDS, followed by a brief rinsing in washing buffer without Triton X-100. 
The gels were then incubated at 37°C for 12-24 h in 50 mM Tris-HCl buffer 
containing 5 mM CaCl2, 1 µM ZnCl2, 1% Triton X-100, 0.02% NaN3, pH 7.6. 
The gels were then stained with Coomassie Brilliant Blue R250 followed by 
destaining with 10% acetic acid, 5% methanol. For reverse zymography 25 ng/ml 
MMP-2 (Chemicon) was added to the 12% or 15% polyacrylamide gels 
containing 1 mg/ml gelatin. Washes and the digestion were performed as 
described for gelatin zymography.  
Pulse-chase analysis and immunoprecipitation  
For pulse-chase studies cells were incubated in methionine-free MEM followed 
by metabolic labeling for 10 min with 250 µCi/ml [35S]-methionine (<1000 
Ci/mmol). The cells were then chased with MEM (over 500-fold excess of 
unlabeled methionine). At the indicated time points the cells were washed and 
lysed with Triton lysis buffer (50 mM Tris-HCl buffer, pH 8.0, containing 150 
mM NaCl, 1% Triton X-100, 0.02% sodium azide, 10 mM EDTA, 10 µg/ml 
aprotinin, 1 µg/ml pepstatin A and 1 µg/ml aminoethylbenzene sulphonylfluoride; 
Calbiochem, San Diego, CA). For immunoprecipitation analysis, cell lysates were 
preabsorbed by incubation with preimmune serum and protein A-Sepharose beads 
at 4°C for 2-20 h. After centrifugation the supernatants were incubated with MT1-
MMP antibodies (2 µg/ml) on ice for 1 h, followed by incubation with protein A-
Sepharose at 4°C for 1 h. The beads were then washed three times with Triton X-
100 lysis buffer and once with PBS. Bound proteins were eluted by reducing 
Laemmli sample buffer and incubation at 95°C for 5 min. The immune complexes 
were resolved by SDS-PAGE and detected by fluorography.  
Purification and N-terminal sequencing of MT1-MMP 
The 60-kDa form of wild-type MT1-MMP was immune affinity purified from 
stable MT1-MMP transfected HT-1080 cell clone using MT1-MMP antibodies as 
described for immunoprecipitation analyses. The 43-kDa form of soluble mutant 
MT1-MMP with six additional C-terminal histidines was purified from ∆TM 
transfected HT-1080 cells using TALON metal affinity resin (Clontech, Palo Alto, 
CA) according to the manufacturer’s protocol. Proteins were dissolved with 
Laemmli sample buffer, resolved by SDS-PAGE and electrotransferred to 
polyvinylidene difluoride membrane (Millipore Corporation, Bedford, MA). After 
staining with Coomassie blue R-250 the bands were excised from the membrane 
and subjected to amino acid sequencing  (Ariad Pharmaceuticals, Cambridge, 
MA).  
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Cell surface biotinylation  
Cells were rinsed at 4°C with PBS and incubated in PBS containing 0.5 mg/ml of 
Sulfo-NHS-biotin (Pierce Chemical, Rockford, USA) on ice for 1 h. The reaction 
was terminated by washing with 10 mM Tris-HCl buffer (pH 7.4) containing 10 
mM glycine, 0.4 M sucrose, and 1.5 mM CaCl2, and 5 mM MgCl2 for 10 min. The 
cells were lysed and subjected to immunoprecipitation with MT1-MMP 
antibodies. The immune complexes were resolved by SDS-PAGE and analyzed 
with peroxidase-conjugated streptavidin (DAKO A/S, Denmark) and enhanced 
chemiluminescence Western blotting detection system (Pierce Chemical). To 
analyze the processing time courses of cell surface biotinylated MT1-MMP 
proteins the cells were surface biotinylated as above, shifted to 37
oC for 
increasing time periods  (0 to 180 min) to allow processing, then lysed, and 
subjected to immunoprecipitation. 
Cell surface cross-linking 
For crosslinking experiments metabolically (50 µCi/ml  35S-methionine) or 
surface (0.2 mg/ml sulfo-NHS-biotin) labeled cells were incubated with 
nonpermeant thiol-cleavable crosslinker DTSSP (1 mM) for 1 h on ice, washed 
and lysed. Aliquots of the lysates were subjected to immunoprecipitation with Ab-
2 against the cytoplasmic domain of MT1-MMP followed by SDS-PAGE under 
nonreducing or reducing (50-100 mM DTT) conditions and detection by 
fluorography or horseradish-peroxidase conjugated streptavidin. Alternatively, the 
cell surface proteins were crosslinked with noncleavable BS
3 crosslinker (0.5 
mg/ml). The cells were then washed and lysed, and aliquots of cell lysates were 
fractioned by SDS-PAGE under reducing conditions and analyzed by 
immunoblotting as indicated. 
In vitro analyses of MT1-MMP cleavage  
Recombinant soluble forms of wt and inactive MT1-MMP (∆TM and 
E240A∆TM, respectively) were expressed in baculovirus/insect cell system and 
purified by cation exchange and gel filtration chromatography (Valtanen et al., 
2000). ∆TM and E240A∆TM (10 ng) were incubated alone or with proteinase 
inhibitors as indicated in 50 mM Tris-HCl buffer, pH 7.5, containing 0.15 M 
NaCl, 10 mM CaCl2, 0.05 % Brij 35 and 0.02 % NaN3 at 37°C for 3 hours. The 
reactions were terminated with reducing Laemmli sample buffer, and the MT1-
MMP fragments were separated by SDS-PAGE and characterized by 
immunoblotting.    
GST-fusion protein purification 
For GST pull-down analyses the noncatalytic GST/MT1-MMP fusion proteins 
were captured from the cell lysates by incubation with glutathione-Sepharose for 
1.5 h at 4°C and washed. The bound proteins were eluted with Laemmli sample  
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buffer, fractionated by SDS-PAGE under nonreducing or reducing conditions, and 
analyzed by immunoblotting with anti-MT1-MMP or anti-GST antibodies.  
Immunofluorescence and internalization assays 
Cells were cultured on glass coverslips, washed with PBS, and fixed with 3% 
paraformaldehyde for 10 min. For intracellular staining the cells were 
permeabilized with 0.1 % Triton X-100 in PBS for 20 min. Subsequently, the 
coverslips were treated with 5% bovine serum albumin in PBS for 30 min. The 
cells were then labeled with the indicated primary antibodies followed by 
Rhodamine- or fluorescein isothiocyanate (FITC)-conjugated secondary 
antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Next, the 
coverslips were washed and mounted on glass slides using Vectashield (Vector 
Laboratories, Burlingame, CA). The fluorescence images were obtained by using 
epifluorescence microscope or a Bio-Rad
 MRC-1024 confocal microscope. For 
internalization assays, the cells were cultured on glass coverslips and washed 
twice with cold PBS containing 1% bovine serum albumin. Cells were then 
incubated with anti-MT1-MMP antibodies (Ab-3) on ice for 1 h, washed and 
shifted to 37
oC for the indicated time periods. Subsequently, the cells were fixed, 
permeabilized, and stained with FITC-conjugated goat anti-rabbit IgG. For co-
localization experiments, cells were labeled with anti-clathrin, dynamin, or EEA1 
primary antibodies followed by Rhodamine- or FITC- conjugated secondary 
antibodies. For the staining of migrating cells, a gel containing serum-free MEM 
and 0.5 % low melting point agar was poured above the cells. Chemoattractant 
gradient was generated to the solid agar gel by adding 1 ng FGF-2 or 5 µl fetal 
calf serum to one side of the coverslips (Alanko et al., 1994). After 24 h the gel 
was removed, and the cells were fixed and labeled with Ab-1 and FITC–
conjugated anti-rabbit antibodies as described above.  
In vitro invasion assay 
The Boyden-chamber cell invasion assay was carried out according to 
manufacturer’s instructions (Becton Dickinson, Bedford, MA). Bowes control 
cells or stably transfected Bowes cells expressing wild-type or mutated MT1-
MMP proteins (1x10
5 cells/ml) were suspended in MEM containing 0.1% BSA 
and seeded onto uncoated or Matrigel-coated Transwell filters (8 µm pore size) in 
invasion chambers. Proteinase inhibitors aprotinin (100 µg/ml), BB-3103 (10 
µM), or CTTHWGFTLC (500 nM) were added to the suspension of control cells 
or cells expressing wt MT1-MMP, and the cells were seeded onto the filters after 
0.5 h incubation. Fetal calf serum (5%) was used as a chemoattractant in the lower 
chambers. After 18 h incubation, noninvading cells were removed from the top 
surface of the filter, and the filters were stained with Diff-Quick (Dade AG, 
Dudingen, Switzerland). Cells migrated onto the lower surface of the filter were 
counted under a microscope at x40 or x200 magnification. Each assay was carried 
out in triplicate, and five fields were counted for each sample.       
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Results 
Differential regulation of MT1-MMP gene expression and 
proMMP-2 activation (I) 
To analyze the function of MT1-MMP and its role on proMMP-2 activation, we 
cloned from a human embryonic lung cDNA library a cDNA for MT1-MMP and 
studied MT1-MMP expression in human HT-1080 fibrosarcoma cells and CCL-
137 embryonic lung fibroblasts. Northern hybridization analysis indicated that 
both cell lines constitutively express endogenous MT1-MMP mRNA. Treatment 
of both cells with PMA caused a 2-3-fold increase in mRNA levels, whereas 
ConA increased MT1-MMP mRNA levels about 4-fold only in CCL-137 
fibroblasts, and TNF-α treatment resulted in a slight increase in MT1-MMP 
mRNA levels only in HT-1080 cells. EGF, bFGF, TGF-β, and IL-1β had no 
significant effects on MT1-MMP expression. The increase in MT1-MMP mRNA 
expression by PMA required protein synthesis, as shown by cycloheximide 
inhibition. The effect of PMA was also inhibited by treatment of the cells with 
dexamethasone. Analysis of MT1-MMP mRNA stability using actinomycin D 
treatment indicated that its half-life was very long and not affected by PMA. 
These data indicate that PMA affects MT1-MMP expression at the transcriptional 
level, since no further increase in mRNA stability could account for the observed 
increase of mRNA levels. 
MT1-MMP overexpression induces proMMP-2 activation (Sato et al., 1994). 
However, only HT-1080 cells had significant proMMP-2 processing activity after 
treatment with PMA or ConA, while fibroblasts were virtually negative. Hence, 
proMMP-2 activation did not directly correlate with MT1-MMP mRNA 
expression. To further characterize the correlation between MT1-MMP expression 
and proMMP-2 activation, we transfected HT-1080 cells with MT1-MMP and 
selected stable transfectants producing about 10-fold excess of MT1-MMP as 
compared with the wild-type HT-1080 cells. Consistent with the primary report 
(Sato et al., 1994), these cells were able to activate proMMP-2. PMA treatment 
further enhanced this activation. These results indicate that whereas 
overexpression of MT1-MMP in some cells results in MMP-2 activation, the 
contribution of other factors is also important. 
To examine the role of potential changes in TIMP-2 expression in the 
activation of proMMP-2, the RNA blots from the experiments described above 
were hybridized with a TIMP-2 cDNA probe. TIMP-2 mRNA was expressed at 
similar levels in both HT-1080 and CCL-137 cells, and none of the chemicals or 
growth factors tested, including PMA, ConA, the calcium ionophore A23187, 
TNF-α, EGF, bFGF, TGF-β, and IL-1β, caused significant changes.   
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Calcium ionophores inhibit proMT1-MMP activation, 
binding of TIMP-2 and MMP-2, and proMMP-2 activation (I, 
II)  
We next hypothesized that posttranslational processing of MT1-MMP may 
regulate its cell surface activity. To study the molecular forms of MT1-MMP 
expressed in HT-1080 and CCL-137 cells we raised polyclonal rabbit antibodies 
against various intracellular and extracellular regions of MT1-MMP. By using 
Ab-2 against the C-terminal cytoplasmic domain we found that MT1-MMP 
zymogen was synthesized as a 63-kDa protein in HT-1080 and CCL-137 cells. 
This zymogen was rapidly N-terminally processed to an activated 60-kDa form 
with N-terminal Tyr
112. Results of immunoblotting analysis revealed that CCL-
137 cells contained mainly activated 60-kDa MT1-MMP. In these cells, PMA and 
ConA substantially increased the levels of activated MT1-MMP without 
considerable proMMP-2 activation. Therefore, neither proMT1-MMP processing 
nor the accumulation of active enzyme was sufficient to promote proMMP-2 
activation in these fibroblasts. 
Previous results of our group have indicated that the activation of proMMP-2 
by HT-1080 cells treated with either PMA, TNF-α, or Con A can be prevented by 
simultaneous treatment of the cells with calcium ionophores or thapsigargin (Lohi 
and Keski-Oja, 1995). This effect is not accompanied by any significant changes 
in MT1-MMP mRNA levels, suggesting an inhibition of some other step in the 
activation process. To understand this inhibition mechanism, we studied the 
effects of calcium ionophores on proMMP-2 activation and MT1-MMP 
processing in transfected MT1-MMP overexpressing HT-1080 cells. Treatment 
with the calcium ionophore ionomycin also prevented proMMP-2 activation in 
these cells, while MT1-MMP mRNA expression remained constant. Indeed, 
ionomycin treatment inhibited the processing of proMT1-MMP to the activated 
60-kDa form. Thus, intracellular calcium levels controlled proMMP-2 activation 
by modulating proMT1-MMP activation. 
Inactivating autocatalytic MT1-MMP cleavage produces 43-
kDa cell-surface and 20-kDa soluble fragments  (I, II, IV)  
The enhanced MT1-MMP mRNA expression by PMA, ConA, or transfection did 
not correlate with the relative level of the activated 60-kDa MT1-MMP in HT-
1080 cells. Instead, the proMMP-2 activation was associated with accelerated 
turnover of MT1-MMP through further N-terminal cleavage to a 43-kDa cell 
surface form. This form was inactive in gelatin zymography unlike the 60-kDa 
MT1-MMP. Portion of soluble C-terminally truncated MT1-MMP mutant was 
also processed to ~43-kDa form. PMA treatment increased the levels of this 
soluble form in a manner similar to that of the wild-type MT1-MMP. The 
cleavage that resulted in the generation of this form occurred at the Ala
255–Ile
256 
bond in the C-terminal part of the catalytic domain as determined by N-terminal  
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sequencing. Overexpression of MT1-MMP induced its cleavage to the 43-kDa cell 
surface form also in human Bowes melanoma cells. During this cleavage a 
soluble, ~20-kDa N-terminal fragment containing the catalytic center was released 
to the culture medium. A synthetic MMP inhibitor, but not a gelatinase specific 
inhibitor, prevented the cleavage suggesting that it was a result of an autocatalytic 
event. Another concomitant cleavage resulted in the release of an active soluble 
~56-kDa form of wt MT1-MMP that was not recognized by antibodies against the 
cytoplasmic domain. Furthermore, purified soluble MT1-MMP was also 
autoproteolytically processed to the 43-kDa and 20-kDa forms in vitro. This 
processing was concentration dependent (data not shown). These results suggest 
that autocatalytic intermolecular inactivating cleavage is a putative mechanism for 
negative regulation of MT1-MMP activity.  
Oligomerization through hemopexin and cytoplasmic 
domains regulates the activity and turnover of MT1-MMP 
(III) 
The formation of multimeric complexes by MT1-MMP may facilitate its 
autocatalytic inactivation or proMMP-2 activation on the cell surface. To test this 
hypothesis, we expressed various glutathione-S-transferase (GST)/MT1-MMP 
fusion proteins in HT-1080 cells and SV-40 transformed human lung fibroblasts 
and analyzed their effects on MT1-MMP activity and potential homophilic 
interactions. We found that crosslinked MT1-MMP was expressed on the cell 
surface as oligomeric 200-240-kDa complexes containing both the active 60-kDa 
and the autocatalytically processed 43-kDa forms. Overexpression of a 
GST/MT1-MMP fusion protein containing the transmembrane and cytoplasmic 
domains of MT1-MMP inhibited the PMA-induced autocatalytic cleavage of 
endogenous MT1-MMP to the 43-kDa species, but not proMMP-2 activation. On 
the other hand, a similar fusion protein with the hemopexin, transmembrane and 
cytoplasmic domains inhibited proMMP-2 activation in a dominant negative 
fashion. These results suggest that both the autocatalytic cleavage of MT1-MMP 
and proMMP-2 activation may be regulated by oligomerization through 
cytoplasmic and hemopexin domains. Indeed, either domain, when attached to cell 
membrane by a transmembrane domain, formed stable homophilic complexes. 
Co-purification of MT1-MMP with these fusion proteins also correlated with their 
cell surface co-localization. 
MT1-MMP targeting through its cytoplasmic domain is 
critical for cell invasion through Matrigel (IV) 
MT1-MMP has transmembrane and cytoplasmic domains, which may target it to 
invasive fronts (Nakahara et al., 1997). To study the effects of the cytoplasmic 
domain of MT1-MMP on its own protein expression, proMMP-2 activation and  
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cell invasion, we expressed MT1-MMP mutants with progressively truncated C-
termini in human Bowes melanoma cells. By immunofluorescence analysis we 
found that wt MT1-MMP was clustered at the leading edge of cells migrating in 
chemotactic FGF-2 gradient. ProMMP-2 was activated in all transfected cell 
clones regardless of cytoplasmic deletions. However, the localization of MT1-
MMP to the leading edge of migrating cells and cell invasion through matrigel 
were strongly enhanced only in cells expressing either wt or truncated MT1-MMP 
lacking 6 C-terminal amino acid residues (∆577). Truncations of 10 or 16 amino 
acid residues in the cytoplasmic domain (∆567 and ∆573, respectively) disturbed 
the clustering of MT1-MMP and gradually decreased MT1-MMP induced 
invasion. To find out if the increased invasion of MT1-MMP transfected cells was 
due to enhanced MMP-2 activity, we compared the effects of a broad spectrum 
MMP inhibitor BB-3103 to those of the cyclic peptide CTTHWGFTLC that 
inhibits MMP-2 and MMP-9, but not MT1-MMP (Koivunen et al., 1999). A 
serine proteinase inhibitor aprotinin was used as a control. The invasion of cells 
expressing wt MT1-MMP was decreased to the level of control cells by BB-3103. 
The CTTHWGFTLC peptide partially inhibited the invasion of MT1-MMP 
overexpressing cells (56 % inhibition) while aprotinin had only a moderate effect.      
Endocytosis in clathrin-coated pits regulates cell surface 
expression of MT1-MMP (V) 
We found that full length MT1-MMP was localized mainly to intracellular 
compartments in various types of cells. ConA, which induces proMMP-2 
activation in HT1080 cells, shifted the majority of endogenous MT1-MMP from 
intracellular compartments to the cell surface. The cytoplasmic truncation mutant 
MT1∆C mimicked this phenotype. In transfected cells, it induced robust 
proMMP-2 activation and was expressed at high levels on the cell surface, while 
wt MT1-MMP localized predominantly to the intracellular compartments and 
induced modest proMMP-2 processing to the intermediate and active forms. In 
addition, ConA increased proMMP-2 activation in wt MT1-MMP transfectants, 
whereas MT1∆C was resistant to this increase, suggesting that ConA may regulate 
MT1-MMP activity by affecting its cytoplasmic domain mediated trafficking. 
Indeed, MT1-MMP was co-localized with clathrin on the plasma membrane and 
Early Endosomal Antigen 1 (EEA1) in endosomes.  Internalization experiments 
revealed that MT1-MMP was internalized rapidly in clathrin coated vesicles while 
MT1∆C remained on cell surface.  Furthermore, co-expression of a dominant 
negative mutant of dynamin, K44A, resulted in elevation of MT1-MMP activity 
by interfering with the endocytotic process. Therefore, inhibition of internalization 
by three different means, i.e., ConA treatment (Luttrell et al., 1997), cytoplasmic 
domain deletion, and co-transfection with dominant negative mutant of dynamin 
K44A, all enhanced the relative cell surface levels of MT1-MMP accompanied by 
elevated proMMP-2 activation.   
  
 50
Discussion 
Cell surface association of secreted proteinases has been recognized as a key 
mechanism to focus degradative processes (Chen, 1992; Mignatti and Rifkin, 
1993). Indeed, in tissues ECM remodeling only occurs in immediate pericellular 
environment. When this work was initiated the first membrane-bound MMP, 
MT1-MMP, had recently been discovered and found to induce cell surface 
proMMP-2 activation and invasive cell phenotype. It had been detected in normal 
tissues and in some forms of cancer. Subsequent studies soon indicated that MT1-
MMP was the first member discovered belonging to the MT-MMP subfamily, but 
only little was known about the regulation of these unique enzymes. In this work 
we first addressed the regulation of MT1-MMP mRNA expression and then I 
concentrated on characterizing posttranslational mechanisms that regulate the 
function of MT1-MMP at the cell surface. The results indicate that rapid zymogen 
activation by removal of the prodomain (II), cell surface events like 
oligomerization (III), clustering (IV), and inactivation by intermolecular 
autocatalytic cleavage of the catalytic domain (I, II, IV), as well as endocytosis of 
MT1-MMP from the cell surface in clathrin coated pits (V) provide cells with 
efficient mechanisms to regulate pericellular proteolysis by MT1-MMP.   
Correlation between MT1-MMP expression and proMMP-2 
activation (I) 
MMP-2 was originally characterized in a malignant mouse tumor as a type IV 
collagen-degrading activity, whose expression in the stromal side of the invasive 
front correlated with metastatic potential and cell transformation (Liotta et al., 
1979; Liotta et al., 1980; Liotta et al., 1981; Salo et al., 1982; Salo et al., 1983). 
During development and tissue remodeling it is expressed by mesenchymal cells 
(Reponen et al., 1992). In addition to the elevated expression levels, the activation 
of proMMP-2 correlates with the invasive cell phenotype (Yamamoto et al., 1996) 
and is likely to be a critical step, which determines the total MMP-2 activity. 
Impaired proMMP-2 activation in MT1-MMP deficient mice indicates the 
physiological role of MT1-MMP in the activation (Zhou et al., 2000).  
On the cell surface, MT1-MMP can co-operate with MMP-2, which is 
secreted by the same cell or by adjacent cells. Mesenchymal cells express both 
these proteinases during development, whereas MT1-MMP may be specifically 
upregulated in endothelial cells and in neoplastic epithelium. Based on 
biochemical and cell culture studies, the proMMP2 activation by the two-step 
proteolytic removal of the prodomain involves the formation of cell surface 
complexes that contain MT1-MMP, TIMP-2, and proMMP-2 (Strongin et al., 
1995; Emmert-Buck et al., 1995; Imai et al., 1996; Overall et al., 1999; Overall et 
al., 2000). We compared MT1-MMP and TIMP-2 expression levels to proMMP-2  
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expression and activation using human CCL-137 embryonic lung fibroblasts and 
HT-1080 fibrosarcoma cells as cell culture models. Both cell types had similar 
baseline expression levels of MT1-MMP and TIMP-2 mRNAs, while the relative 
expression level of MMP-2 was higher in fibroblasts than in HT-1080 cells. MT1-
MMP mRNA expression could be regulated by treatments with growth factors or 
chemicals: PMA increased this expression in both cell types, whereas TNF-α was 
effective only in HT-1080 cells and ConA only in fibroblasts. TIMP-2 and MMP-
2 mRNA levels remained virtually constant during these treatments. However, 
proMMP-2 activation occurred only in PMA or ConA treated HT-1080 cells. 
Thus, the activation did not directly correlate with increased MT1-MMP mRNA 
expression even in fibrosarcoma cells suggesting that regulation by other 
mechanisms is also important. 
Role of MT1-MMP processing/activation in proMMP-2 
activation (II) 
In the trimolecular cell surface complexes the N-terminal inhibitory domain of 
TIMP-2 binds to the catalytic site of MT1-MMP (Strongin et al., 1995; Zucker et 
al., 1998; Fernandez-Catalan et al., 1998; Hernandez-Barrantes et al., 2000), while 
the C-terminal region of TIMP-2 interacts with the C-terminal domain of 
proMMP-2 (Overall et al., 1999). Therefore, proMT1-MMP activation by either 
proteolytic removal of the prodomain or conformational change to expose the 
catalytic site of MT1-MMP is a prerequisite for the complex formation. In the first 
characterization of the complexes the purified endogenous MT1-MMP had N-
terminal Tyr
112 (Strongin et al., 1995). Thus, the prodomain had been removed. 
Later, an intracellular activation mechanism by Golgi-associated proprotein 
convertase furin was characterized for the soluble truncated MT1-MMP (Pei and 
Weiss, 1996; Sato et al., 1996). We found that in COS-7 cells, which express 
endogenous furin, the transiently transfected full length MT1-MMP was 
detectable only as the 63-kDa zymogen (I). In addition, the requirement of the 
proteolytic removal of the N-terminal prodomain of MT1-MMP for cell surface 
MMP-2 activation has been questioned (Cao et al., 1996; Cao et al., 1998; Cao et 
al., 2000). However, fibrosarcoma cells and fibroblasts differed from COS-7 cells 
in that both endogenous and transfected MT1-MMP was rapidly processed to the 
activated 60-kDa MT1-MMP with N-terminal Tyr
112 beginning right after the 
furin recognition sequence. This processing/activation of MT1-MMP was 
prevented by ionomycin. Concomitantly, the binding of TIMP-2 and MMP-2, and 
proMMP-2 activation were inhibited, suggesting that the MT1-MMP complex 
formation and subsequent proMMP-2 activation depended on MT1-MMP 
processing. Since these observations, substantial evidence supporting the 
activation of also full-length MT1-MMP during or upon transport to cell surface 
by furin-like proteinases has emerged (Maquoi et al., 1998; Kurschat et al., 1999; 
Yana and Weiss, 2000; Aznavoorian et al., 2001; Rozanov et al., 2001a). In 
addition, the endogenous MT1-MMP is rapidly activated and detectable  
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predominantly in the activated 60-kDa form in all cultured cells that we have 
tested. Therefore, it is likely that most cells, which express MT1-MMP, have the 
capacity to constantly process it to the activated form, which can then act with 
TIMP-2 as a receptor for proMMP-2.   
Several reports have indicated that at low concentrations TIMP-2 induces 
MT1-MMP mediated MMP-2 activation, whereas at high concentrations it 
prevents the activation (Strongin et al. 1995; Butler et al., 1998; Kinoshita et al., 
1998; Hernandez-Barrantes et al., 2000). MT1-MMP is capable for the initial 
cleavage in MMP-2 prodomain that results in 68-kDa intermediate form of MMP-
2, whereas the final activation occurs through autocatalytic MMP-2 cleavage. 
Because TIMP-2 inhibits the catalytic site of the “receptor” MT1-MMP, 
neighboring TIMP-2 free MT1-MMP is likely to do the initial cleavage in the 
MMP-2 prodomain. In this model excess of TIMP-2 inhibits the proteolytic 
activity of all MT1-MMP molecules and, hence, proMMP-2 activation. The 
TIMP-2 mRNA was expressed at similar levels in HT-1080 cells and fibroblasts, 
and was not affected by PMA or ConA treatment. However, the levels of both 
cell-bound TIMP-2 and proMMP-2 protein were higher in fibroblasts than in HT-
1080 cells. This was reflected by accumulation of activated 60-kDa MT1-MMP 
more potently in PMA and ConA-treated fibroblasts than in respective HT-1080 
cells. Thus, it is likely that binding of TIMP-2 and proMMP-2 to the activated 
MT1-MMP on the surface of fibroblasts stabilizes activated MT1-MMP and 
exhausts free active MT1-MMP available for proMMP-2 activation. Accordingly, 
other studies have confirmed that the formation of the trimolecular complexes is 
not sufficient for activation, rather the activation of bound proMMP-2 requires 
overexpression of MT1-MMP, treatment of cells with ConA, phorbol esters, or 
cultivation of cells in the presence of special ECM components (Overall et al., 
2000). In certain conditions an alternative mechanism to activate MT1-MMP bound 
proMMP-2 may be through serine proteinases like thrombin and cell surface 
uPAR/uPA/plasmin pathway (Schwartz et al., 1998; Lafleur et al., 2001a; Lafleur 
et al., 2001b; Monea et al. 2002). 
Autocatalytic MT1-MMP inactivation (I, II, IV) 
We found one direct correlation between MT1-MMP protein expression and 
proMMP-2 activation in HT-1080 cells. In these cells enhanced MT1-MMP 
mRNA expression did not correlate with accumulation of the active enzyme, but it 
resulted in further N-terminal processing of the activated 60-kDa MT1-MMP to 
the 43-kDa form within 1-4 h after translation (I, II). During this cleavage soluble, 
~20 kDa N-terminal fragment containing the catalytic site was released to the 
conditioned medium (IV). Neither of these fragments retained gelatinolytic 
activity detectable by zymography. Since our primary reports, others have also 
reported the existence of 40-45 kDa cellular forms of MT1-MMP, usually in 
association with proMMP-2 activation (Stanton et al., 1998; Ellerbroek et al., 
1999; Theret et al., 1999; Annabi et al., 2001a; Annabi et al., 2001b; Gingras et  
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al., 2000; Maquoi et al., 2000; Ellerbroek et al., 2001; Rozanov et al., 2001a; 
Zhuge and Xu, 2001). Hernandez-Barrantez et al. (Hernandez-Barrantes et al., 
2000) found that in their vaccinia virus expression system either co-expression or 
addition of exogenous TIMP-2 is actually required for the detection of the active 
MT1-MMP as well as for proMMP-2 activation. Otherwise, MT1-MMP is 
processed to 40-44 kDa membrane bound forms. A portion of soluble mutant 
form of MT1-MMP was proteolytically processed in a manner similar to that of 
the wild-type enzyme in HT-1080 cells (II). We determined the N-terminal 
sequence starting at Ile
256 for this inactive 43-kDa form of soluble MT1-MMP. On 
the other hand, the 44-40 kDa MT1-MMP bands of wt MT1-MMP from vaccinia 
virus infected BS-C-1 cells starts at Gly
285, and is therefore lacking the whole 
catalytic domain. In both cases the ~43 kDa forms represent catalytically inactive 
fragments. Lack of catalytic activity for the soluble 20-kDa remnant suggests that 
the 43-kDa form with Ile
256 is the predominant form.  
Stanton et al. (Stanton et al., 1998) demonstrated that at least soluble MT1-
MMP, MMP-2, MMP-3 and MMP-13 can process membrane bound MT1-MMP 
to the inactive form in vitro. In addition, synthetic metalloproteinase inhibitors 
and TIMP-2 inhibit the processing (Stanton et al., 1998; Ellerbroek et al., 1999), 
while TIMP-1 that is a poor inhibitor of MT1-MMP (Will et al., 1996) has no 
effect on processing. We found that E240A point mutation in the catalytic domain 
of MT1-MMP prevented the inactivating cleavage in human Bowes melanoma 
cells (IV). These results suggest that MT1-MMP is involved in the processing, 
either directly or through activation of another proteinase. Bowes cells do not 
express detectable levels of MMP-13 (Airola et al. 1999), which has also been 
characterized as a potential substrate for MT1-MMP (Knäuper et al., 1996b). 
Activated MMP-2 and MT1-MMP itself were therefore the best candidate 
proteases responsible for the cleavage. However, the gelatinase specific inhibitory 
peptide (Koivunen et al., 1999) did not prevent MT1-MMP processing, and the 
processing of C-terminally truncated MT1-MMP mutants did not correlate with 
proMMP-2 activation, suggesting that MMP-2 was not involved in MT1-MMP 
inactivation (IV). In vitro experiments with recombinant soluble forms of wt and 
E240A MT1-MMP confirmed that the catalytically active MT1-MMP was able to 
cause the cleavage (IV). This cleavage was concentration dependent suggesting 
that it is an intermolecular event (data not shown). Based on these results we 
proposed that at the sites of high focal activities a putative mechanism for 
negative regulation of MT1-MMP activity is an autocatalytic inactivating 
cleavage. At the same time Hernandez-Barrantes (Hernandez-Barrantes et al., 
2000) also reported that the processing occurs independently of MMP-2.  
Identification of oligomeric MT1-MMP complexes (III) 
The primary evidence for the presence of homo-oligomeric MT1-MMP 
complexes in HT-1080 cells came from crosslinking experiments of endogenous 
and transfected wt MT1-MMP with the identification of the cell surface ~200- 
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240-kDa complexes composed of mainly the 60-kDa and 43-kDa species. The 
complex sizes suggest assembly of MT1-MMP to tetramers. However, the 
apparent molecular weight of oligomers in gels did not necessarily increase 
exactly according to the molecular weights of the monomers. In addition, the 
complex sizes based on the migration in SDS-PAGE were determined under 
nonreducing conditions, where MT1-MMP monomers migrate slightly faster than 
under reducing conditions. The 200-240 complexes could therefore also 
correspond, for example, to pentamers or hexamers of MT1-MMP. Alternatively, 
they may contain other protein(s) that have long half-lives and are not efficiently 
biotinylated and therefore not detected by our metabolic labeling and cell surface 
biotinylation experiments. By co-purification analysis of wt and C-terminally 
truncated MT1-MMP forms with N-terminally truncated MT1-MMP, we 
demonstrated that both hemopexin and cytoplasmic domains, when attached to the 
cell membrane by the MT1-MMP transmembrane domain, formed stable 
homophilic interactions. Based on these results we proposed a model where MT1-
MMP forms oligomers, apparently dimers and tetramers, by interactions through 
the hemopexin and cytoplasmic domains. We designated these as type I and II 
interactions, respectively (Fig. 3). 
The formation of disulfide bonds between Cys
574 residues on the cytoplasmic 
tails of neighboring MT1-MMP monomers may stabilize type II interactions as 
reported recently (Rozanov et al., 2001a). However, in our experimental 
conditions, without crosslinking, the cell surface biotinylated MT1-MMP proteins 
migrated on SDS-PAGE mainly as monomers even under nonreducing conditions, 
and only a minor proportion was detectable as dimers or other complexes (data 
not shown). The purified ∆Cat/Pex- and ∆Cat/MT1-MMP complexes migrated 
under nonreducing conditions mainly as dimers indicating stabilization by 
disulfide bonds. However, it is possible that these bonds were formed by 
spontaneous oxidation during the cell extraction and purification processes. 
Nevertheless, our results do not rule out the possibility that MT1-MMP would be 
regulated on the cell surface by transient intermolecular disulfide bond formation 
between the cytoplasmic domains. 
It remains unclear whether the wt MT1-MMP molecules form oligomeric 
complexes on the control HT-1080 cells via both types of interactions. In contrast 
to  ∆Cat, the ∆Cat/Pex that lacks most of the hemopexin domain did not co-
localize or co-purify with endogenous MT1-MMP in these cells without PMA or 
ConA stimulation. Type I interactions through hemopexin domain could also be 
multivalent supporting complexing of more than two molecules. Therefore, it is 
possible that type II interactions through the cytoplasmic domain only transiently 
regulate the function of these complexes in stimulated cells. An associated event, 
such as binding or release of another protein, phosphorylation or other 
modification of the cytoplasmic tail may modulate type II interactions. 
Cytoplasmic domain interaction may then induce conformational changes in 
MT1-MMP, which may in turn affect its proteolytic activity. Alternatively, 
extracellular events such as association or dissociation of the ternary complex,  
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interactions with ECM or cell surface proteins, and autocatalytic cleavage of 
MT1-MMP to the 43-kDa form may induce changes, which in turn affect type II 
interactions. In any case, these observations suggest an intriguing role for the 43-
kDa form, which lacks the catalytic site. Instead of being only a side product as 
previously suggested (II, Overall et al., 2000), it may also regulate adjacent active 
MT1-MMP. 
ProMMP-2 activation and autocatalytic MT1-MMP 
inactivation in the oligomeric complexes (II, III, IV) 
Two proteolytic events associated with MT1-MMP, namely the initial cleavage of 
proMMP-2 in MT1-MMP/TIMP-2 receptor to intermediate form, and the 
intermolecular autocatalytic MT1-MMP cleavage to the 43-kDa form, are 
presumably dependent on a close proximity of at least two MT1-MMP molecules. 
We found that the interactions between the hemopexin domains (type I 
interactions) were critical for the MT1-MMP mediated proMMP-2 activation, and 
those between its transmembrane/cytoplasmic domains (type II interactions) 
regulated the turnover of the enzyme to the 43-kDa form (III). Itoh et al. (2001) 
also provided evidence for homophilic MT1-MMP hemopexin domain 
interactions and their importance for proMMP-2 activation and cell invasion. 
In the MT1-MMP oligomers, a portion of MT1-MMP molecules presumably 
binds TIMP-2 and proMMP-2 forming the trimolecular receptor complex 
(Strongin et al., 1995). Three proteolytic events may then occur in these 
complexes (see Fig. 3): [1] MT1-MMPs cleave the proMMP-2 molecules bound 
to the neighboring MT1-MMP to the 64-kDa intermediate form (Butler et al., 
1998; Kinoshita et al., 1998); [2] autocatalytic processing of two 64-kDa MMP-2 
molecules generate the 62-kDa form (Atkinson et al., 1995; Will et al., 1996), 
and; [3] MT1-MMP cleaves the other TIMP-free MT1-MMP to the 43-kDa form 
(I, II, IV). The effects of ∆Cat/Pex and ∆Cat on these proteolytic steps support 
this model (Fig. 3; III). ∆Cat/Pex, which is capable of type II interactions but not 
of type I interactions competitively inhibits the formation of normal oligomeric 
complexes and prevents the processing of MT1-MMP to the 43-kDa form. 
However, ∆Cat/Pex cannot prevent MT1-MMP dimerization through hemopexin 
domains (type I interactions) or proMMP-2 activation, although proMMP-2 
activation is reduced to some extent. ∆Cat, on the other hand, prevents the 
formation of the normal oligomeric complexes by competing with both type I and 
type II interactions in a dominant negative fashion. Consequently, both MT1-
MMP processing to the 43-kDa form and MMP-2 activation are completely 
blocked.   
We were unable to identify TIMP-2 and MMP-2 from the crosslinked cell-
surface complexes (III). While faint biotinylated protein bands possibly 
corresponding to the co-precipitated TIMP-2 and MMP-2 were detectable with 
long exposures of the reduced samples in the crosslinking analyses (data not 
shown), our immunoblotting analyses of the same immunoprecipitates were not  
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sensitive enough to identify them directly. Previously, we have observed co-
precipitation of MMP-2 with MT1-MMP from HT-1080 and CCL-137 cells 
without crosslinking as assessed by gelatin zymography. Together, these 
experiments suggest that only a minor proportion of MT1-MMP molecules form 
ternary complexes with TIMP-2 and MMP-2 in these cells or that the half-life of 
such complexes is relatively short.  
The concentration dependence of the MT1-MMP cleavage to the 43-kDa 
form and its prevention by dominant negative mutants suggest that it is an 
intermolecular event (III, IV). This is also supported by the observation that N-
terminally truncated ∆Cat mutant lacking the catalytic domain was also cleaved 
by wt MT1-MMP (data not shown). In the cell surface oligomers, homophilic 
hemopexin domain interactions appear to facilitate this autocatalytic cleavage 
(Fig. 3). The release of active MMP-2 to the culture medium and the accelerated 
turnover of MT1-MMP via the 43-kDa form in HT-1080 cells have been 
suggested to result from in trans cleavage of the “receptor” MT1-MMP by the 
neighboring free MT1-MMP (Overall et al., 2000). TIMP-2 inhibits autocatalytic 
MT1-MMP cleavage and the detection of 43-kDa form correlates with the down-
regulation of TIMP-2 by degradation through MT1-MMP-dependent mechanism 
(Maquoi et al., 2000). However, whether TIMP-2-bound MT1-MMP can be 
processed at low TIMP-2 concentrations to the 43-kDa form by adjacent MT1-
MMP, is unclear.  
In the 200-240-kDa oligomers, only a minor proportion of MT1-MMP 
appears to be occupied by TIMP-2 (III), but the exact relationship between TIMP-
2 binding and oligomerization is not known. Within the oligomer, the catalytic 
sites of some MT1-MMP molecules may be buried from TIMP binding, thus 
positioning more than one TIMP-2 free MT1-MMP molecules close to each other. 
TIMP-2 binding may also prevent or affect the level of MT1-MMP 
oligomerization. In addition, interactions with αVβ3 integrin may modulate the 
assembly and function of MT1-MMP complexes. Indeed,  the 43-kDa form of 
MT1-MMP has been co-purified with αVβ3 integrin from surfaces of crosslinked 
MCF-7 cells, which had been co-transfected to express MT1-MMP and β3 integrin 
(Deryugina et al. 2001a). The intermediate form of MMP-2 can bind to αVβ3 
integrin and MT1-MMP can also process αV integrin (Deryugina et al. 2001b).  
Of the characterized autocatalytic cleavage sites the Gly
284-Gly
285  bond 
(Hernandez-Barrantes et al., 2000) between the catalytic domain αC helix and the 
flexible hinge region may be exposed for cleavage of TIMP-2 bound MT1-MMP, 
while the Ala
255-Ile
256 bond near the Met-turn in the catalytic domain is shielded 
by interacting TIMP-2 (Fernandez-Catalan et al., 1998; Overall et al.1999). In the 
vaccinia virus gene transfer system MT1-MMP rapidly undergoes processing to 
40-44 kDa forms without co-expressed TIMP-2 (Hernandez-Barrantes et al., 
2000). This processing is only partially inhibited by exogenously added TIMP-2. 
When the expression levels of transfected MT1-MMP are very high in individual 
cells, the normal machinery for post-translational modifications and transport of 
the protein may be overloaded. Consequently, most of the protein detected may   
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Figure 3.  Model for MT1-MMP oligomerization. A) Wild-type MT1-MMP (wt) exists 
mainly as oligomers, potentially tetramers bound together by two types of interactions on 
the HT-1080 cell surface. Homophilic type I (I on figure) interactions through the 
hemopexin domains are co-operative with type II (II) interactions, which occur through 
the cytoplasmic domains. Type II interactions may involve regulation by disulfide bond 
formation between Cys574 residues in the cytoplasmic domain, as suggested recently. 
Type II interactions may also bring together two dimers to a tetrameric conformation or 
stabilize dimers bound together by type I interactions. Type I interactions may also be 
multivalent. Some of the cell surface MT1-MMP molecules bind TIMP-2 through the 
catalytic center, and this TIMP-2 binds proMMP-2 forming a ternary complex. The three 
proteolytic events occurring in the complexes are the following: [1] MT1-MMPs cleave 
the proMMP-2 molecules bound to the neighboring MT1-MMP to their 64-kDa 
intermediate forms; two 64-kDa MMP-2 molecules cleave each other in an 
intermolecular autocatalytic event to the 62-kDa form, and; the TIMP-free MT1-MMP 
cleaves another free MT1-MMP to the 43-kDa inactive form. Alternatively, autocatalytic 
MMP-2 maturation may in some cellular systems also involve interactions of 
intermediate MMP-2 forms with avb3 integrin (Brooks et al. 1996). B) These proteolytic 
events are affected by the non-catalytic MT1-MMP mutants as follows: ∆Cat/Pex, which 
is capable of type II interactions but not of type I competes with the formation of normal 
oligomeric complexes and inhibits MT1-MMP processing to 43-kDa form. However, 
∆Cat/Pex cannot prevent MT1-MMP dimerization through the hemopexin domains (I) or 
proMMP-2 activation. ∆Cat, which can form complexes through both type I and II 
interactions prevents the formation of dimeric and higher oligomeric complexes of wt 
MT1-MMP by competition in a dominant negative fashion. Therefore, MMP-2 activation 
is completely prevented (modified from III). 
represent functionally inactive protein that accumulates and may be degraded 
along the secretory pathway. Furthermore, the ~20-kDa fragment exhibits no 
gelatinolytic activity in zymography, in contrast to the shed soluble 56 kDa MT1-
MMP, suggesting that the cleavage to this form occurs within the catalytic 
domain. Initial cleavage in other exposed parts of the catalytic domain could also 
induce conformational change to expose the Ala
255-Ile
256 bond for cleavage as 
discussed (English et al., 2001a). However, at least mutations in the MT-loop 
region have no effect in the formation of ~43-kDa form (English et al., 2001a). In 
addition, the release of the single ~20-kDa soluble fragment recognized by the 
Ab-3 (raised against amino acids corresponding to the MT-loop region) does not  
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support this option. Simultaneous detection of two distinct autocatalytically 
truncated cell-surface MT1-MMP forms has also been reported suggesting that the 
cleavage may occur at distinct sites (Rozanov et al., 2001a). 
   
MT-MMP targeting and trafficking during cell migration (IV, 
V) 
Interactions of MT1-MMP with cytoskeletal protein complexes or aggregation 
with integrins can potentially induce MT1-MMP clustering to specific sites at the 
cell surface. In contrast to wt MT1-MMP chimeric MT1-MMP containing the 
transmembrane and cytoplasmic domains of IL2 receptor α-chain does not 
localize to specialized cell surface protrusions called invadopodia or induce 
invasion of RPMI7951 melanoma cells (Nakahara et al., 1997). We found that 
MT1-MMP was clustered at the leading edge of human Bowes melanoma cells 
migrating in chemotactic FGF-2 gradient, and that the truncation of the 
cytoplasmic domain abolished both the clustering of the enzyme and MT1-MMP-
induced cell invasion through reconstituted basement membrane (Matrigel) 
matrixes (IV). The results suggest that the cytoplasmic domain, and especially the 
amino acid residues between Thr
567 and Ser
577 in the middle part of MT1-MMP, 
were essential for the regulation of the MT1-MMP clustering and invasion 
promoting activity. Later studies have confirmed the cytoplasmic domain 
dependent mechanism to promote cell invasion through reconstituted basement 
membrane matrixes (Gingras et al., 2001; Rozanov et al., 2001a; Uekita et al., 
2001). By contrast, direct MMP-2-independent MT1-MMP activity against fibrin 
and type I collagen in transfected MDCK cells is dependent on transmembrane 
localization, but not on cytoplasmic domain (Hiraoka et al., 1998; Hotary et al., 
2000).  
Membrane trafficking is likely to be one key mechanism to regulate MT1-
MMP activity. The cytoplasmic domain of MT1-MMP has a C-terminal valine 
that may affect the activation of MT1-MMP and its transport from endoplasmic 
reticulum to the plasma membrane (Urena et al., 1999). However, C-terminally 
truncated MT1-MMP mutants (∆567, ∆573 and ∆577), all lacking the C-terminal 
valines, were transported to the cell surface, and we observed no intracellular 
accumulation of 63-kDa proenzyme or glycosylated 80-84 kDa forms, as was 
reported by Urena et al. (Urena et al., 1999). In fact, the cell surface levels of the 
C-terminally truncated mutants were comparable or higher as compared to the wt 
MT1-MMP. On the other hand, a variety of PDZ-domain containing proteins, 
which interact with receptors having C-terminal valines are involved in 
cytoplasmic protein complexes. These proteins may modulate various trafficking, 
clustering, and signaling events. Therefore, identification of specific interactions 
and their potential effects on MT1-MMP function in different cell types and in 
response to different stimuli are required to characterize the role of the C-terminal 
valine in MT1-MMP function.    
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Interestingly, we found that endocytosis in clathrin coated pits provides cells 
with a mechanism to down-regulate cell surface levels of MT1-MMP. Inhibition 
of internalization by ConA treatment (Luttrell et al., 1997), cytoplasmic domain 
deletion, or co-transfection with dominant negative mutant of dynamin K44A 
enhanced the cell surface levels of MT1-MMP accompanied by elevated 
proMMP-2 activation. Therefore, it remains possible that transient increase in 
proteolytic activity can be achieved by temporary inhibition of MT1-MMP 
endocytosis, perhaps, mediated by the cellular machinery through its cytoplasmic 
domain. On the other hand, excessive MT1-MMP activity may be disposed of 
rapidly by enhancing its internalization through the same cytoplasmic domain.  In 
essence, an “on/off” or “up/down” switch might have been built into the 
cytoplasmic domain to regulate MT1-MMP activity. Thus, the cytoplasmic 
domain appears to play a critical role in MT1-MMP mediated proteolysis by 
controlling not only its localization but also its magnitude. Uekita et al. (2001) 
subsequently reported that the dileucine and tyrosine residues in the MT1-MMP 
cytoplasmic domain were important for interaction with µ2 subunit of adaptor 
protein 2, and internalization in clathrin coated pits. Consistent with our results 
about the effects of cytoplasmic truncations on cell invasion (IV) they found that 
cytoplasmic mutations, which prevent internalization, also abolish the invasion 
promoting function of MT1-MMP suggesting that dynamic turnover of MT1-
MMP at the edge of the cell is important for migration through matrigel. On the 
other hand, they also confirmed that transmembrane anchorage was sufficient for 
the invasion in fibrillar collagen matrix.  
To bring all this to a context of a fibroblastic cell (see Fig. 4), under baseline 
situation MT1-MMP is slowly synthesized (I, II), it is constitutively activated 
during transport to cell surface (I, II), where it may interact with adjacent MT1-
MMP molecules to form oligomers (III, Itoh et al., 2001), most likely tetramers, 
and with TIMP-2 and proMMP-2. Cytoplasmic interactions with clathrin-coated 
pit components direct MT1-MMP for internalization (V, Uekita et al., 2001). 
During overexpression in stimulated or transfected cells, the MT1-MMP 
synthesis, activation, and transport to cell surface are accelerated, and the 
extracellular TIMP-2 levels are decreased (Maquoi et al. 2000). Consequently, 
MT1-MMP activates MMP-2 and inactivates adjacent MT1-MMP molecules at 
the cell surface complexes (III).  When the cells receive signals for directional 
migration like in chemotactic FGF-2 gradient, MT1-MMP is clustered at the cell 
leading edge through a mechanism that depends on cytoplasmic, and potentially 
extracellular interactions (IV). In addition to the potential interactions with multi-
protein complexes of cytoplasmic and transmembrane proteins, interactions of the 
hemopexin domain with ECM molecules such as collagen may modulate MT1-
MMP assembly. Recent reports have also characterized novel extracellular 
proteins that may positively or negatively regulate MT1-MMP mediated 
proMMP-2 activation (Miyamori et al., 2001; Nakada et al., 2001). At the cell 
surface complexes, the autocatalytically cleaved 43-kDa forms may negatively 
regulate adjacent active MT1-MMP molecules (III, Itoh et al., 2001), and 
overexpression of corresponding dominant negative mutant also inhibit cell  
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migration (Itoh et al., 2001). However, in the case of endogenous MT1-MMP or 
transfected wt MT1-MMP the accelerated turnover to 43-kDa form and elevated 
internalization correlates well with enhanced MT1-MMP activity and cell 
migration. Therefore, the accelerated MT1-MMP turnover and internalization 
during cell migration may be a mechanism for cells to provide continuous 
proteolysis to the sites of invasion.   
 
 
 
Figure 4. Function of MT1-MMP in fibroblasts. MT1-MMP zymogens are constitutetively 
synthesized in endoplasmic reticulum. They are constantly activated during transport 
through Golgi networks to the cell surface (I, II), where the activated enzyme mainly 
exists as oligomers (III, Itoh et al., 2001), and interact with TIMP-2 and MMP-2. In the 
oligomers MT1-MMP activates proMMP-2 and inactivates adjacent MT1-MMP 
molecules (III). In migrating cells cytoplasmic and potential extracellular interactions 
direct MT1-MMP oligomers to the leading edge. MT1-MMP is then rapidly internalized 
in clathrin-coated vesicles (V, Uekita et al., 2001). Potential MT1/MMP dimerization 
through cytoplasmic disulfide bonds, and recycling and caveolae mediated 
compartmentalization events are indicated with question marks.    
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Perspective 
MT1-MMP and potentially also other MT-MMPs are important for normal 
development and cancer. They are, therefore, being studied extensively. Several 
recent findings have begun to reveal the complexity of the temporally and 
spatially coordinated regulation of proteolytic, adhesive, and signaling events 
occurring at both sides of the plasma membrane during morphogenic and invasive 
processes. In the current work we found that MT1-MMP activity may be regulated 
by various posttranslational mechanisms including autocatalytic inactivation, 
assembly to oligomers and clusters, and membrane trafficking. However, the 
details of these and other regulatory processes and the regulation in vivo are 
poorly understood. Future work to compare these processes involving type I 
transmembrane or GPI-anchored MT-MMPs as well as related families of 
membrane-anchored proteinases should shed light on the mechanistic and 
functional aspects of pericellular proteolysis. In addition, new data about the 
structural and biochemical properties of distinct MT-MMPs, and their complexes 
with inhibitors, substrates, and other specific binding proteins should help to 
understand their structure-function relationships.  
Currently it is unclear, which factors determine whether MT1-MMP acts 
directly towards ECM components or activates MMP-2 to act during different 
physiological processes. The initial characterization of the MT1-MMP deficient 
mice suggested a significant role for the enzyme in connective tissue 
collagenolysis, which is further supported by substantial in vitro evidence. 
However, given the long and continuously growing list of potential MT1-MMP 
and MMP-2 substrates it is possible only to speculate of the specific proteolytic 
events, which modulate, for example, vascular invasion and chondrocyte 
proliferation. Therefore, one of the most challenging future goals in MMP 
research is the definition of significant in vivo substrates for these enzymes. 
Towards this end, the generation of transgenic animals with either tissue-specific 
overexpression or gene inactivation of distinct MT-MMPs and their combinations 
is important. Detailed characterization of these mice and comparison to other 
transgenic mice with related phenotypes should bring valuable new information. 
In addition, although I have here emphasized the regulation by posttranslational 
events, MT1-MMP expression is clearly upregulated in various forms of cancer 
and during developmental processes. In the near future, DNA and protein 
microarrays will provide large amounts of expression data, which should help to 
resolve the interplay between the regulatory cascades that determine cell 
phenotype.   
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